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RÉSUMÉ ET MOTS CLÉS FRANÇAIS 
L'hypertension essentielle est une maladie complexe affectée par des facteurs 
génétiques et environnementaux. Il est estimé que des facteurs génétiques contribuent entre 
30% et 50% de la variation de la pression artérielle (PA) observée. L'identification des 
gènes peut apporter une meilleure compréhension sur la pathophysiologie de la maladie: 
Les souches de rats consanguins sont utilisées dans cette étude sont le rat 
hypertendu Dahl sensibles au sel (S) et le rat normotendu Lewis (LEW). Mon étude se 
concentre sur le chromosome 8 (C8) du rat. Une étude antérieure des liaisons génétiques 
suggère qu'une région du C8 contient un locus pour le trait quantitatif (QTL) de la PA. 
L'objectif de cette étude consiste à vérifier si ce QTL existe et de le localiser à une région 
précise sur C8. Des lignées congéniques, obtenues par le croisement du rat S et du rat 
LEW, de façon à remplacer des régions du C8 du rat S, adjacentes et non chevauchants, par 
les régions homologues du rat LEW, permettent d'associer un changement potentiel de la 
PA à une région sur le C8. Les mesures du PA ont été faites par télémétrie. Des deux 
lignées congéniques produites, les allèles LEW d'une des souches baissent la PA (p<0.001). 
Par contre, les allèles LEW de la deuxième souche congénique augmentent la PA 
(p<O.OOI). Cette étude prouve qu'il existe sur la C8 deux QTLs de la PA, adjacents, mais 
séparés, avec des effets opposés ce qui n'a pas été observé dans les études antérieures de 
liaisons. 
Mots-clés: Hypertension essentielle; rat Dahl sensibles au sel; locus pour trait 
quantitatif; modèle animal; lignées congéniques; facteurs génétiques; chromosome 8 
IV 
ENGLISH ABSTRACT AND KEYWORDS 
Essential hypertension is a complex disease with genetic and environmental factors. 
It is estimated that 30 to 50 % of the variations observed in blood pressure (BP) is caused 
. 
by genetic factors. The identification of the genes that affect BP is crucial for a full 
comprehension of the pathophysiology of the disease. 
My study focuses on rat chromosome 8 (C8). According to previous linkage studies, 
C81ikely contains one quantitative trait locus (QTL) for BP. The purpose ofmy study is to 
determine whether such a QTL exists, and if so, to assess its effect on BP. Our basic 
strategy is to use congenic strains. Our congenic strains were constructed from inbred 
strains with contrasting effects on BP regulation, namely the hypertensive Dahl Salt-
Sensitive (S) strain and the normotensive Lewis (LEW) strain. Non-overlapping, adjacent 
C8 regions of the S rat were replaced with homologous regions of the LEW rat. BP was 
measured by telemetry. Of the two congenic strains produced, LEW alle1es of one congenic 
strain lower BP (p<0.001). In contrast, LEW alleles of the other increase BP (p< (0.001). 
Thus, two BP QTLs on C8, adjacent to each other, but with opposite effects exist on C8. 
The effect of the second, novel QTL has not been reported in previous linkage studies. 
Keywords: essential hypertension; salt-sensitive Dahl rat; quantitative trait locus; animal 
model; congenic strain; genetic factors; chromosome 8 
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REVIEW OF THE LITERATURE 
Chapter 1 
Hypertension: Clinical features of hypertension 
1. 1 The Cardiovascular System 
The cardiovascular system is an organ system whose function is to propel and 
transport blood and its constituents throughout the body. The components of the 
cardiovascular system are: the blood, the heart and blood vessels(67). 
Blood consists of liquid plasma and ceIls. It is the medium by which substances 
such as nutrients, hormones, gases (oxygen, carbon dioxide) and metabolic wastes are 
transported to and removed from tissues. The vascular system is made up of arteries, veins, 
and capillaries (blood vessels), which carry blood to and from aIl tissues (Figure1). 
The heart pumps blood at a high pressure through the vascular system. It sends 
blood to the lungs for oxygenation and via the aorta, distributes oxygenated blood to the 
tissues of the body.1t is a four-chamber pump, with the right side receiving deoxygenated 
blood from the body at low pressure and pumping it to the lungs (the pulmonary 
circulation) and the left side receiving oxygenated blood from the lungs and pumping it at 
high pressure around the body (the systemic circulation)(20,95). It can also help stabilize 
body temperature, oxygen concentration, ionic composition, osmolarity and pH as part of 
homeostasis(119,124). 
Figure 1 - The Cardiovascular System 
Pulmonary 
Circuit 
Systemic 
Circuit 
ORGANS 
2 
The cardiovascular system is comprised of the heart, with its four chambers; arteries, in which 
blood moves away from the heart; veins, in which blood retums to the heart; and a system of 
capiUaries, which transport blood between smaU arteries and smaU veins. The cardiovascular 
system is further divided into the pulmonary circuit, which delivers deoxygenated blood to 
the lungs, and the circulatory circuit, which delivers oxygenated blood to aU of the organs and 
tissues. 
/ , 3 
1.1.1 Hemodynamics of Circulation 
The primary determinants of systemic blood pressure (BP) are cardiac output (CO) 
and peripheral vascular resistance. CO is the amount of blood ejected per minute by the left 
ventricle into the aorta or by the right ventricle into the pulmonary trunk. It is determined 
by plasma volume, cardiac stroke volume, heart rate and myocardial contractility. It is 
calculated as CO (mLlmin)= Stroke Volume (SV) (mLibeat) x Heart Rate (HR) 
(beats/min), where SV the amount ofblood ejected by a ventricle during each systole. SV is 
related to the stretch of the heart before it contracts, the forcefulness of the contraction and 
the resulting pressure before ventricular ejection begins. Peripheral vascular resistance is a 
function of the balance of humoral vasoconstriction and vasodilation, adrenergic activity 
and arteriole smooth muscle tone. CO and peripheral vascular resistance are the primary 
determinants of systemic BP. Given the se two factors, mean arterial BP is calculated as CO 
x peripheral vascular resistance. 
Extremely complex physiological networks and other factors underlie BP 
regulation and hypertension susceptibility. Arterial BP is generated by the left ventricle 
ejecting blood into the systemic vasculature, which acts as a resistance to CO. With each 
ejection ofblood (ventricular systole), the aortic blood volume increases, stretching the 
wall of the aorta. As the heart relaxes (ventricular diastole), blood flows from the aorta into 
distributing arteries that distribute the blood to the various organs. Within the organs, the 
arterial vasculature undergoes extensive branching and the vessel diameters decrease. The 
smaller arteries and arterioles serve as the chief resistance vessels. Through changes in their 
diameter, they serve to regulate systemic vascular resistance and organ blood flow. In 
hemodynamic terms, the mean arterial pressure (MAP) can be described by MAP (CO x 
SVR) + CVP, where SVR = systemic vascular resistance, and CVP central venous 
pressure. Therefore, increases in CO, SVR or CVP willlead to increases in MAP 
(95,119,124). 
1.2 Definition of hypertension 
The general term "blood pressure" was coined in the early 1700s by the man who tirst 
measured it, the Reverend Stephen Hales ofEngland (75,112). The expression "blood 
pressure" (BP) refers to the arterial pressure in systemic circulation. The movement of 
4 
blood throughout the organism depends on the strength of the heartbeat and on the pressure 
gradient in the cardiovascular system. BP is dependent on cardiac pressure and vascular 
resistance. BP is highest in the aorta and progressively decreases as the blood flows further 
away from the heart. So the pressure gradient is such that there is a progressive lowering of 
BP as the blood travels from large arteries to small ones, then from the capillaries back 
through the veins, until it returns to the heart atria through the vena cava. BP is measured in 
millimetres of mercury (mmHg). 
The cardiac cycle consists oftwo parts: systole (contraction of the heart muscle in 
the ventricles) and diastole (relaxation of the ventricular heart muscles). When the 
ventricles contract, they force the blood out of the heart into the arteries. The left ventricle 
empties into the aorta (systemic circuit) and the right ventricle into the pulmonary artery 
(pulmonary circuit). The he art valves open and close to limit flow to a single direction. 
During cardiac diastole BP fluctuates between a maximum value and a minimum value 
(diastolic blood pressure (DBP) or diastolic arteriai pressure (DAP)). The systolic blood 
pressure (SBP) or systolic arterial pressure (SAP) is a measure of the BP within the artery 
at the moment when the heart contracts (ventricular contraction) and ejects blood towards 
the arteries. DBP corresponds to the BP when the heart relaxes and the aortic valve closes 
(BP between ventricular contraction). Mean arterial pressure (MAP) is the average between 
DBP and SBP. MAP is a measure that reflects the BP to which small blood vessels are 
continuously submitted to. 
When the values for these pressures are chronically elevated, the condition is called 
hypertension. Hypertension is defined in general as a chronic elevation in BP in the arteries, 
when compared to values that are considered normal. In general, hypertension is defined as 
a BP systolic value ~ 140 mmHg or diastolic value ~ 90 mmHg (i.e. values exceeding 
140/90 mmHg), or both. The official criteria on threshold values for hypertension vary, but 
the criteria set by the World Health Organization (WHO) are widely referred to (Table 1) 
(75). 
Elevated BP is a common and powerful predisposing factor for stroke, coronary 
disease, cardiac failure and peripheral artery disease, imposing a 2-3 fold increased risk of 
one or more ofthese atherosclerotic sequelae. The risk ratio imposed by hypertension is 
greatest for cardiac failure and stroke, but in Western countries coronary disease is the most 
common and lethal hazard (88). 
Table 1 -Classification of hypertension 
CATEGORY Systolic Diastolic 
(mm Hg) (mm Hg) 
Optimal < 120 < 80 
Nonnal < 130 < 85 
High-nonnal 130-139 85-89 
Grade 1 hypertension (mild) 140-159 90-99 
Subgroup: borderline 140-149 90-94 
Grade 2 hypertension (moderate) 160-179 100-109 
Grade 3 hypertension (severe) ~180 ~110 
Isolated systolic hypertension 2:.140 <90 
Subgroup: borderline 140-149 <90 
Table adapted from Hansson, L. Hypertension management in 2002: where 
have we been? where might we be going? Am. J Hypertens. 15, 101S-
107S (2002). (75) 
1.2.1 Types of Hypertension 
5 
Hypertension affects 15-30% of the human population, including 50 million 
Americans. The two main categories of hypertension are primary hypertension, also known 
as essential hypertension, and secondary hypertension. The vast majority of patients have 
essential hypertension, which is a fonn with no identifiable underlying cause(95). 
Unknown genetic and environmental factors are thought to play a role in the pathogenesis 
of essential hypertension. Secondary hypertension, which accounts for only 5-10% of cases 
is due to definable causes such as renal vascular disease, chronic renal failure, renal artery 
disease, thyroid disease pregnancy and endocrine abnonnalities such as, primary 
hyperaldosteronism (95). 
6 
1.2.1.1 Primary or Essential Hypertension 
Despite many years of research, there is no unifying hypothesis to account for the 
pathogenesis of primary hypertension. There is a natural progression of this disease that 
suggests that early elevations in blood volume and CO might initiate increased resistance in 
the systemic vasculature. In hypertensive patients, the vascular endothelium produces less 
nitric oxide and the vascular smooth muscle is less sensitive to the actions of this powerful 
vasodilator. There is also an increase in endothelin production, which can enhance 
vasoconstrictor tone. Many mechanisms may operate to initiate and sustain hypertension. 
Treatment of patients with primary hypertension generally involves 
pharmacological intervention (2) to modify factors such as angiotensin II, sympathetic 
activity and calcium entry into cells so as to reduce arterial pressure. These treatments do 
not target the underlying disease. Nevertheless, treatment of hypertension with 
antihypertensive drugs is important, because hypertension increases the risk for coronary 
artery disease, strokes, renal disease and other disorders. The three broad classes of drugs 
used to treat primary hypertension are diuretics (to reduce blood volume), vasodilators (to 
decrease systemic vascular resistance), and cardioinhibitory drugs (to decrease CO). 
Essential hypertension is further subdivided into a monogenic form and polygenic forms. 
1.2.1.1.1 Monogenic Form of Hypertension 
In the monogenic form of essential hypertension, the phenotype is due to lesions or 
mutations in a single gene, leading to eg., overproduction of mineralocorticoids. This form 
is also known as the Mendelian form of hypertension. The monogenic form of hypertension 
is only responsible for only 5% of cases (41,81). Mendelian forms of hypertension incIude 
Liddle's syndrome, glucocorticoid remediable aldosteronism, apparent mineralocorticoid 
excess and pseudohypoaldosteronism type II. The examples previously listed affect the 
homeostasis of salt and water reabsorption. Even though Mendelian forms of hypertension 
are more rare and severe than essential hypertension, there is a tremendous effort to better 
understand their etiology in the hope that it would lead to cIues about the pathophysiology 
of essential hypertension (51,55,185,186,199). 
Figure 2 - Factors Contributing to Essential Hypertension 
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different genetic factors. 
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1.2.1.1.2 Polygenic Form of Hypertension 
Polygenic hypertension is caused by the interaction of many genes, as opposed to 
the monogenic form, which is due to a single gene. It is also influenced by environment 
factors and the interaction between environmental factors and genetic factors (Figure 2). 
90-98% of aIl patients with primary hypertension suffer from polygenic hypertension (178). 
For example, it has long been known that hypertension aggregates in certain 
families. Familial clustering of high BP could be the consequence of inheritance of a BP 
gene or genes, household environment, or a combination ofboth. Familial aggregation 
studies have shown that clustering occurs early in life since siblings living apart do not 
become dissimilar and spouses do not become more similar even though they share the 
same environment. Phenotyping hypertension is remarkably complex because of the 
difficulty of accurately measuring BP and the vast variety of factors regulating BP. For 
example, BP is partly determined by the pumping action of the heart, so it is inherently 
pulsative in character. What is more, an individual 's BP varies by time of day, se as on and 
other circumstances such as stress and emotions (137). 
1.2.1.2 Secondary Hypertension 
Figure 3 - Various Ways Certain Conditions Cause Secondary Hypertension 
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Disease conditions increase either cardiac output or systemic vascular 
resistance or both, and thereby increase blood pressure. 
Adapted from Klabunde, R.E. Cardiovascular physiology concepts (2005) (95). 
Secondary hypertension is the direct result of another disease or condition such as 
obesity, thyroid, or adrenal dysfunction. These conditions increase either SVR or CO or 
both, which in tum results in hypertension (Figure 3). The most common conditions 
resulting in secondary hypertension are as follows. 
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Renal artery disease: Renal artery disease causes stenosis, which is the narrowing 
of the vessellumen. The reduced lumen diameter increases the pressure drop along 
the length of the diseased artery, which reduces the pressure at the afferent arteriole 
in the kidney. Reduced arteriolar pressure and reduced renal perfusion stimulate 
rennin release by the kidney. This increases circulating angiotensin H (ATH) and 
aldosterone. These honnones increase blood volume by enhancing renal 
reabsorption of sodium and water. Increased ATH causes systemic vasoconstriction 
and enhances sympathetic activity. Chronic elevation of ATH promotes cardiac and 
vascular hypertrophy. The net effect of these renal mechanisms is an increase in 
blood volume that augments CO. Therefore, hypertension caused by renal artery 
stenosis results in an increase in both SVR and in CO. 
Primary hvperaldosteronism: This is the increased secretion of aldosterone, which 
generally results from adrenal adenoma or adrenal hyperplasia. Increased circulating 
aldosterone causes renal retention of sodium and water, so blood volume and 
arterial pressure increase. Furthennore, the adrenal medulla secretes more 
catecholamines (epinephrine and norepinephrine). Activation of the sympathetic 
nervous system also increases circulating A TU, aldosterone, and 
vasopressin, which can increase SVR. Prolonged elevation of A TH and 
catecholamines can lead to cardiac and vascular hypertrophy, both of which can 
contribute to a sustained increase in BP. 
Stress: Physical or psychological stress leads to activation of the sympathetic 
nervous system, which causes increased release of norepinephrine from sympathetic 
nerves in the heart and blood vessels. This leads to increased CO and increased 
SVR. 
Sleep Apnea: Sleep apnea is a disorder in which people repeatedly stop breathing 
for short periods oftime (10-30 seconds) during their :;leep. lndividuals suffering 
from sleep apnea have a higher incidence of hypertension. 
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Hyperthvroidism: This results from an excess ofthyroid hormone induces systemic 
vasoconstriction, an increase in blood volume, and increased cardiac activity, all of 
which can lead to hypertension. 
Pheochromocytoma: This occurs when catecholamine secreting tumours in the 
adrenal medulla give rise to high levels of circulating eatecholamines, both 
epinephrine and norepinephrine. Thus, the tumours th(:mselves produce epinephrine 
and norepinephrine. The presence of these hormones k~ads to systemic 
vasoconstriction and cardiac stimulation, both ofwhicfl contribute to significant 
elevations in BP. 
Aortic coarctation: This is the narrowing of the aorta, typically just distal to the left 
subclavian artery, is a congenital defect that obstructs ,:lOrtic outflow, leading to 
elevated BP proximal to the coarctation (i.e., elevated arteriai pressures in the head 
and arms). Reduced systemic blood flow and reduced renal blood flow lead to an 
increase in the release ofrenin and an activation of the renin-angiotensin-
aldosterone system (RAAS). This in tum elevates bloüd volume and BP. Although 
the aortic arch and carotid sinus baroreceptors are exposed to higher than normal 
pressures, the baroreceptor reflex in blunted due to structural changes in the walls of 
vessels where the baroreceptors are located. AIso, baroreceptors become 
desensitized to chronic elevation in pressure and become "reset" to the higher 
pressuree 95,124). 
1.3 Traditional risk factors for hypertension 
1.3.1 Salt sensitivity 
"Hence, if too much saIt is used, the pulse hardens" Huang Ti 2600 BCE. This 
ancient wisdom of Chinese doctors shows us for how long sodium has been associated with 
circulatory effects (130), and thus it is maybe the most studied risk factor predisposing for 
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hypertension. Large studies, like Intersalt (46-48,174-176), have linked sodium and BP 
convincingly. Moreover, primitive people with diets low in salt have no hypertension. 
However, the response ofBP to variations in dietary salt intake is quite heterogeneous. In 
sorne hypertensive individuals, decreases in BP as a result of !;alt restriction are clinically 
significant, while in others little or no change in BP occurs, whereas in others, BP may 
actually increase with salt restriction(193). Salt-sensitive patknts are also more likely than 
salt-resistant patients to exhibit left ventricular hypertrophy, microalbuminuria, and 
metabolic abnormalities. These effects naturally make salt-sensitive individuals attractive 
subjects for genetic studies(l75,181 ,194, 196-198). 
An individual's sensitivity to dietary salt may also be related to ethnic background, 
gender, and other environmental factors. For example, the decline in the glomerular 
filtration rate with age is more marked in individuals of Africm origin. Also, in a study of 
more than 400 hypertensive subjects, seven missense mutations were found in the gene 
coding for the ~-ENaC subunit of the amiloride-sensitive sodium channel, most ofthem in 
patients of African-American descent. Sorne of the ENaC pol:rmorphismsmight be 
associated with greater ENaC activity in vivo and contribute to ethnic differences in sodium 
retenti on and the risk of low-renin hypertension (180). 
The identification of several molecular mechanisms lillking dietary salt and 
hypertension confirm that saltsensitivity and BP are not determined by a single gene but 
rather by the combined action of a number of genes. Each of these genes may affect one or 
more channels, transporters, or enzymes associated with the neural, hormonal, vascular, and 
renal mechanisms affecting BP. For example, salt-sensitive hypertension may be associated 
with changes not only in vascular mechanisms but also in the renal Na+/Ca2+ exchanger 
protein (93). A high-salt diet may affect cellular mechanisms not only in vascular smooth 
muscle, but also in the endothelium. Sorne studies have ShOWIL that an increase in aortic 
basal tone in Cl2-Na+ -K+ -ATPase deficient mice that is depend(mt on the endothelium(93). 
AIso, homozygous II-HSD2-deficient mice that exhibit impaired renal sodium excretion 
may have an additional endothelial dysfunction, as demonstra:~ed by enhanced 
norepinephrine-induced vascular contraction, which may contribute to hypertension(93). 
It is thought that changes in BP normally serve as a physiological response whose 
purpose is to maintain sodium balance and extracellular volume within normallimits. 
Impairment of the mechanisms responsible for the pressure-natriuresis relationship will 
cause BP levels to ri se in order to achieve the adjustments in urinary sodium excretion 
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required to maintain homeostasis. The BP regulatory system i:; thereby reset at a higher BP 
lev el (158). 
1.3.2 Alcohol 
Heavy alcohol intake has been found to associate with hypertension (120) .Up to 
now, no signalling mechanism has been discovered that could c1early explain this link. 
Among the male Caucasian population, SBP and DBP increase with the quantity of alcohol 
consumed. In male African-Americans on the other hand, there is a greater increase in 
diastolic pressure for comparable quantities of alcohol consumed. This tendency is also 
observed in women, but the increase in BP is less pronounced (5,116,120,140). 
1.3.3 Obesity 
Studies of the genetic epidemiology of obesity have suggested that the 
predisposition for development of obesity is partly geneticaUy determined 
(5, Il,77,171,174). Obesity is a leading risk factor for essential hypertension. Obese people 
have also more left ventricular hypertrophy than lean individu ais. Those who weigh the 
most have, on the average, the highest BP of a given age group. Losing weight reduces BP 
and left ventricular hypertrophy. However, it has also been loug known that not aU obese 
individuals are hypertensive and vice versa. AdditionaUy, in Sl)me populations, such as 
Mexican-Americans and African-Americans, obesity seems t(l have less effect on the 
development of hypertension than in Caucasians (193). 
1.3.4 Insulin Resistance 
Insulin resistance syndrome, also known as metabolic syndrome or "syndrome X", 
is a condition which is characterized by a combination of pathologies including 
hypertension, diabetes, abdominal obesity, and dyslipidemia, :unong others. This syndrome 
is very significant when considering the genetic makeup of the hypertensive population 
(13,149-155,164). 
Insulin is a polypeptide hormone secreted by the pancreas. Its main purpose is to 
regulate the levels of glucose in the body antagonistically with glucagon through negative 
feedback loops. It also exhibits vasodilatory properties. 
Insulin resistance is characterized by a blunting of the body's normal reaction to the 
regulating influence of insulin, resulting in an over-production of insultin to compensate. It 
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Îs one of the causes of diabetes and is the main cause of obese individuals being diabetic. In 
the hypertensive patients with insulin resistance, the reduction in MAP, after a glucose 
load, was blunted, when compared to insulin-sensitive hypertt::nsive patients and 
normotensive patients (172). In normotensive and insulin-sen!:itive hypertensive 
individuals, insulin may stimulate sympathetic activity without elevating MAP 
(117).Though it is known that diabetes often appears simultaneously with hypertension, the 
mechanism or mechanisms, causing syndrome X have yet to l:'e discovered. 
1.3.5 Gender, Age and BP 
Men generally have a higher mean BP than women, regardless of age. As for SBP, 
men also have higher levels than women during early adulthood. Above the age of sixt y, 
the opposite becomes true (138). DBP, on the other hand, tends to be slightly higher in men 
than in women regardless of age. 
The prevalence of hypertension increases progressively with age in both men and 
women. However, for BP there is a sexual dimorphism (14,160). For women, although 
long-term studies such as the Framingham(78,90) have not documented a rise in BP with 
menopause, other studies have found significantly higher SBP and DBP in postmenopausal 
compared to pre-menopausal women, even after adjustment for age and body mass index 
(160). According to these studies, postmenopausal women are twice as likely to have 
hypertension than pre-menopausal women. This menopause-œlated increase in BP has been 
attributed to a variety of factors, including estrogen withdrawal, over-production of 
pituitary hormones, weight gain, or perhaps a combination ofthese and other yet undefined 
neurohumorai influences. 
Androgen is thought to play a role in the sex differenœs in BP, though its effects 
are more pronounced in men. One possible mechanism may b~ the blunting of the pressure-
natriuresis relation (138). Female sex hormones and their receptors may also be implicated 
in BP differences between men and women. Though no significant associations have been 
detected between estrogen receptor genes and BP among women, a genetic association 
study by the Victorian Family Heart Study investigators found that men înheriting the "a" 
allele on the estrogen receptor a gene had significantly higher SBP levels (5 mm Hg) than 
men with other genotypes (49,138). 
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Increased age is an important risk factor for higher BP (160), since it may reflect the 
accumulation of different factors predisposing for hypertension as weIl as factors related to 
normal aging, such as pre-programmed senescence or just general wear and tear (167,170). 
1.4 High BP as a Risk Factor for Morbidity and End-Organ Damage 
Hypertension is one of the most important risk factors for cardiovascular diseases 
(66). The risk of coronary heart disease and stroke increases with increased BP. Patients 
who do not control high BP face a reduced life span, because hypertension can cause 
certain organs to deteriorate over time. Sorne of the most com.TIon complications of 
hypertension are listed in Table 2. 
For the heart, for example, high BP contributes to 75% ofall strokes and heart 
attacks, according to the National Heart, Lung, and Blood Institute. Compared with normal 
individuals, hypertensive people can have as high as ten times the risk of stroke and five 
times the risk of a heart attack, depending on the severity of the hypertension. The risk for 
developing congestive heart failure is also significantly higher with increased BP. People 
whose high BP has led to enlargement of the left side of the h,~art (left ventricular 
hypertrophy) remain at risk for strokes, heart attacks, sudden death, and heart failure even 
after their BP is under medical control. 
Hypertension is also implicated in kidney dysfunction and in calcium retenti on 
problems. High BP causes 30% of aIl cases of kidney failure, a rate that is second only to 
diabetes. Animal studies have indicated that when heart cells ,~nlarge in response to high 
BP, they undergo molecular changes that cause an abnormal release of calcium, a mineraI 
crucial for healthy heart contractions. This defect appears to be irreversible. Hypertension 
also increases the elimination of calcium in urine, which in tum may lead to loss ofbone 
mineraI density (136,188). This is a significant risk factor for fractures, particularly in 
elderly women. 
Cardiovascular disease, (CVD) shares most of the saIne risk factors as hypertension, 
su ch as age, smoking, dyslipidemia, particular personality characteristics (aggressive or 
type A personality), diabetes and obesity. For example, excess alcohol consumption 
predisposes to acute cardiac events, whereas it has been suggested that moderate alcohol 
consumption protects against CVD morbidity (89). On the other hand, left ventricular 
hypertrophy, a form of CVD, is a common complication ofh~lpertension. It is a powerful 
risk factor for coronary artery disease and sudden death, independent of alcohol 
consumpti one 191 ). 
Table 2-Hypertension and end organ damage 
Cardiac 
Coronary heart disease 
Myocardial infarction (heart attacks) 
Sudden death 
Cerebrovascular 
Cerebral thrombosis / hemorrhage 
Hypertensive encephelopathy 
Renal 
Microalbuminuria 
Chronic renal insufficiency 
Other 
Carotid artery stiffening 
Arterial aneurysms 
Left ventricular 
hypertrophy 
Diastolic dysfunction 
Congestive heart failure 
Dementia and reduced 
cognitive function 
Stroke 
Retinopathy 
From L. Hasson article "Assessment of hypertensive organ danage" (118) 
1.5 Factors Regulating Arlerial BP 
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BP and blood flow is part of the homeostatic system regulated by feedback 
mechanisms. Information on BP and blood flow is picked up by sensory receptors, mainly 
baroreceptors and chemoreceptors( 16), and transmitted to higher brain regions such as the 
cerebral cortex, the limbic system and the hypothalamus (123,200). These regions transmit 
regulatory responses along sympathetic nerves (cardiac accelerator nerves and vasomotor 
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nerves) and opposing parasympathetic nerves (vagus nerves). The endocrine system is also 
implicated in the complex homeostasis ofBP. 
The following scheme (Figure 4) summarizes the general factors that regulate CO and 
SVR. 
Figure 4 - Factors Affecting Mean BP 
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Mean arterial pressure is regulated by changes in cardiac output and systemic vascular 
resistance. See text for details. 
Adapted from Klabunde, 2005 (95). 
MAP is regulated by changes in SVR and CO. The SVR depends on the vascular 
anatomy, in vascular, tissue and neurohumoral factors. CO, on the other hand is the product 
of stroke volume (SV) and heart rate (HR), while SV is a function ofventricular preload 
(defined as the initial stretching of the cardiac myocytes prior to contraction) and inotropy. 
Ventricular preload is dependent on venous compliance and blood volume, which itself 
relies on sodium and water handling by the kidneys. Neurohumoral factors control CO 
indirectly, by directly affecting HR, inotropy, venous compliance and sodium and water 
regulation in the kidneys. Genes that regulate any component ofthis scheme will modify 
MAP. 
SVR is determined by the anatomy of the vascular network. Generally, vascular 
structure remains relatively constant; however, certain pathological conditions, such as 
vascular thrombosis can affect the number ofperfused blood vessels. Furthermore, other 
pathological conditions can result in changes in the relative number of parallel and series 
resistance elements of the vascular network. 
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The most important mechanism for changing SVR involves changes in vessel 
lumen diameter. In chronic hypertension, vessel radius is often reduced due to thickening of 
the vessel wallleading to a reduction in lumen size. Vascular factors su ch as nitric oxide, 
endothelin, and prostacyclin also influence vessel diameter. Furthermore, myogenic 
mechanisms intrinsic to the vascular smooth muscle can also dter vessel diameter. Tissue 
factors (e.g., adenosine, potassium ion, hydrogen ion, histamine) are chemicals released by 
parenchymal cells surrounding blood vessels and can significantly alter vessel diameter. In 
general, tissue factors are involved with regulating organ blood flow more so than systemic 
arterial pressure; however, any change in vessel tone will affect both organ blood flow and 
systemic arterial pressure. Finally, neurohumoral mechanisms play a very important role in 
regulating SVR and BP (2,95). 
1.5.1 Neural Regulation of BP 
1.5.1.1 The Nervous System 
The, nervous system is the system of cells, tissues, and organs that regulates the 
body's responses to internaI and external stimuli. The nervous system is divided into two 
parts, the central nervous system (CNS) and the peripheral neJVOUS system (PNS). 
The central nervous system (CNS) represents the largest part of the nervous system, 
including the brain and the spinal cord. The peripheral nervou; system consists of the 
nerves and neurons that extend outside the CNS , such as the nerves in the limbs and 
organs. 
The peripheral nervous system is divided into the somatic nervous system and the 
autonomie nervous system (ANS). The somatic nervous system includes aIl the neurons 
connected with the muscles, sense organs and skin. It consists of afferent fibers that receive 
information from external sources and efferent fibers that are responsible for muscle 
contraction. It is responsible for receiving external stimuli and. for the voluntary control of 
body movements through the action of skeletal muscles. 
The ANS is the part of the nervous system that controls homeostasis. It does so 
mostly by controlling cardiovascular, digestive and respiratory functions. The ANS is 
further divided into the sympathetic nervous system (SNS) and the parasympathetic 
nervous system (PNS), which typically function in opposition, complementing each 
other.The SNS is involved in actions requiring quick responses, while the PNS is involved 
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in actions that do not require immediate reaction. The SNS act3 via adrenergic receptors, a 
class of guanosine nucleotide-binding regulatory prote in -coupled receptors that are targets 
of catecholamines. Adrenergic receptors specifically bind theil' endogenous ligands, the 
catecholamines epinephrine and norepinephrine and are activated by these. The PNS acts 
via muscarinic receptors. Receptors that are membrane-bound acetylcholine receptors are 
more sensitive to muscarine than to nicotine. Those, for which the contrary is true, are 
known as nicotinic acetylcholine receptors. 
1.5.1.1.1 Innervation of the Vasculature 
The ANS is controlled from the medulla, located in the: brainstem above the spinal 
cord. The medulla receives sensory input from various system:lc and central receptors (e.g., 
baroreceptors and che more cep tors) as weIl as signaIs from other brain regions (e.g., the 
hypothalamus). Autonomic outflow from the brainstem is divided principally into 
sympathetic and parasympathetic (vagal) branches. Efferent fibers ofthese autonomic 
nerves travel to the heart and blood vessels where they modulate the activity of these 
organs. 
Cardiac function is altered by neural activation. Symp~cthetic stimulation increases 
heart rate, inotropy (contractility), and conduction velocity, whereas parasympathetic 
stimulation of the heart has opposite effects. Sympathetic and parasympathetic effects on 
heart function are mediated by beta-adrenoceptors and muscarinic receptors, respectively. 
Blood vessels and nerves travel primarily along the same pathways in the body. 
Sympathetic adrenergic nerves travel along arteries and are found in the adventitia (outer 
walls of a blood vessels). Varicosities, which are small enlargl!ments along the nerve fibers, 
are the site ofneurotransmitter release. Capillaries receive no mnervation. Activation of 
vascular sympathetic nerves causes vasoconstriction of arteries and veins mediated by 
alpha-adrenoceptors. The release of acetylcholine (ACh) from parasympathetic nerves has a 
direct vasodilatory action. ACh release is often coupled to nitric oxide formation and 
guanylyl cyclase activation. 
The SNS, the fast-acting component of the ANS, play~: a major role in the 
regulation of arterial pressure. The norepinephrine-releasing, ~;ympathetic adrenergic nerves 
that innervate the heart and blood vessels are postganglionic efferent nerves. Within the 
medulla are located sympathetic excitatory neurons that have ,ignificant basal activity, 
which generates a level of sympathetic tone to the heart and v:lsculature even under basal 
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conditions. The sympathetic neurons within the medulla recei'/e input from other neurons 
within the medulla (e.g., vagal neurons), from the nucleus tractus solitarius (which receives 
input from peripheral baroreceptors and chemoreceptors), and from neurons located in the 
hypothalamus. Together, these neuronal systems, with the PNS, regulate outflow to the 
heart and vasculature(2,91 ,95,123,124,183). 
1.5.1.1.2 Arterial Baroreceptors 
Baroreceptors are pressure sensors that furnish the mo:;t immediate input to the 
negative feedback systems that regulate arterial BP. Arterial baroreceptors are located in 
the carotid sinus at the bifurcation of external and internaI carotids and in the aortic arch. 
The aortic arch baroreceptors are innervated by the aortic nene, which then combines with 
the vagus nerve, traveling to the brainstem. Arterial baroreceptors are sensitive to stretching 
of the walls of the vessels in which the nerve endings lie. Incr,!ased stretching augments the 
firing rate of the receptors and nerves, and recruits additional afferent nerves. 
The carotid sinus receptors respond to pressures ranging from 60-180 mmHg. The 
receptors within the aortic arch have a higher threshold pressure and are less sensitive than 
the carotid sinus receptors. Therefore, the carotid sinus receptors are the dominant type of 
arterial baroreceptor. Maximal carotid sinus sensitivity occurs near the normal mean arterial 
pressure. This "set point" changes during hypertension, heart jàilure, and other disease 
states. Receptors are sensitive to the rate of pressure change a!; well as to the steady or 
mean pressure. Therefore, at a given mean arterial pressure, d,!creasing the pulse pressure 
(SBP minus OBP) decreases the baroreceptor firing rate. This is important during 
conditions such as hemorrhagic shock in which both pulse pœssure and mean pressure 
decrease. The combination of reduced mean pressure and reduced pulse pressure reinforces 
the baroreceptor reflex (2,16,91). 
1.5.1.1.2.1 How Baroreceptors Respond to a Sudden Change in BP 
Baroreceptors function as "sampling areas" for many homeostatic mechanisms 
involved in maintaining BP. A decrease in arterial pressure (rnean, pulse or both) results in 
decreased baroreceptor firing. The "cardiovascular center" wilhin the medulla responds by 
increasing sympathetic outflow and decreasing parasympathe1ic outflow. Under normal 
physiological conditions, baroreceptor firing exerts a tonic inhibitory influence on 
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sympathetic outflow from the meduIla. Therefore, hypotension results in a disinhibition of 
the medullary centers. These autonomic changes cause vasoconstriction (increased SVR), 
tachycardia and positive inotropy. The latter two changes increase CO. The increases in CO 
and SVR then lead to a partial restoration ofBP. 
1.5.1.1.3 The Cardiovascular Center 
The cardiovascular center (CVC)(119) is located in thE: meduIla oblongata. It 
controls the neural and honnonal negative feedback systems that regulate BP and blood 
flow. Groups ofneurons within the CVC regulate BR, contractility ofventricles and blood 
vessel diameter. The CVC receives infonnation from the cerehral cortex, limbic system, 
and hypothalamus, as weIl as from sensory receptors: proprioc:eptors, baroreceptors, and 
chemoreceptors. The response signaIs flows along sympathetic and parasympathetic 
neurons of the ANS. 
Neural control ofBP occurs via negative feedback loo])s (Figure 5) that occur as 
two types ofreflexes: baroreceptors and chemoreceptors. The two most important 
baroreceptors are the carotid sinus reflex and the aortic reflex. The carotid sinus reflex 
helps regulate BP in the brain, while the aortic reflex helps regulate systemic BP. 
The chemoreceptors monitor the chemical composition of the blood. They consist of 
the carotid and aortic bodies, which are located close to the carotid sinus reflex and the 
aortic reflex, respectively. They detect changes in blood level of oxygen, carbon dioxide, 
and hydrogen ions 
Figure 5 - How the Cardiovascular Center Regulates Blood Pressure 
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1.5.2 Neurohumoral Mechanisms - The Endocrine System 
The heart and vasculature are regulated, in part, by neural (autonomie) and humoral 
(cireulating) factors. Neural mechanisms primarily involve sympathetic adrenergic and 
parasympathetic cholinergie branches of the autonomie nervous system. In general, the 
sympathetic system stÏmulates the heart and constricts blood vessels, resulting in a rise in 
arterial BP. The parasympathetic system depresses cardiac function and dilates selected 
vascular beds. Humoral mechanisms, on the other hand directly or indirectly alter cardiae 
funetion, vaseular funetion, and arterial pressure. Important humoral systems include 
circulating catecholamines, the renin-angiotensin system, vasopressin (antidiuretic 
hormone), atrial natriuretic peptide, and endothelin. 
1.5.2.1 Hormones 
A hormone is a substance, usually a peptide or steroid, conveyed by the 
bloodstream to effect physiological activity, such as growth or metabolism. They are 
primarily derived from vascular tissues, but are produced also in the adrenal gland, kidney 
and brain. Hormones play important roi es in the physiology and pathophysiology of sodium 
and water balance. 
1.5.2.1.1 Renin-Angiotensin-Aldosterone System 
The renin-angiotensin-aldosterone system (RAAS) (Figure 6) plays an important 
role in regulating blood volume, BP, and cardiac and vascular function. Pathways for the 
RAAS have been found in a number of tissues. The main output ofthe RAAS is 
angiotensin II (ATII), a vasoconstrietor involved in salt excretion and control of 
baroreceptor functions, among others. A TIl is derived from angiotensinogen, a circulating 
protein present throughout the body, in a two-step process. 
ln the first step, angiotensinogen undergoes proteolytic c1eavage by renin to form 
the deeapeptide angiotensin 1 (ATI). The most important site for renin release is the kidney. 
Sympathetic stimulation, renal artery hypotension, and deereased sodium delivery to the 
distal tubules stimulate the release ofrenin by the kidney. The second step involves further 
cleavage of two amino aeids from A TI, produeing the octapeptide A TIl. One mechanism 
for this cleavage is angiotensin-converting enzyme (ACE), which is almost entirely 
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localized within the vascular endothelium, particularly in the lungs. In addition to ACE-
dependent A TIl generation, non-ACE pathways for A TIl generation have also been 
identified, such as the chymotrypsin-like serine protease, chymase.(113) Chymases are 
found in mast cells in many tissues and species. Chymase is thought to be responsible for 
>80% of tissue A TIl formation in the human heart and >60% of that in the arteries.( 54,131) 
ATH has several very important functions (19)(Table 3), inc1uding vasoconstriction, 
dipsogenesis, increased cardiac contractility and the release of catecholamines from nerve 
endings, aldosterone from the adrenal gland and vasopressin from the posterior pituitary 
resulting in renal sodium and water absorption. It constricts resistance vessels (via ATIl 
receptors) thereby increasing SVR and BP. It acts upon the adrenal cortex to release 
aldosterone, which in tum acts upon the kidneys to increase sodium and fluid retention. It 
stimulates the release ofvasopressin (antidiuretic hormone, ADH) from the posterior 
pituitary, which acts upon the kidneys to increase fluid retention. It stimulates thirst centers 
within the brain. It facilitates norepinephrine (NE) release from sympathetic nerve endings 
and inhibits NE re-uptake by nerve endings, thereby enhancing sympathetic adrenergic 
function. It stimulates cardiac hypertrophy and vascular hypertrophy. 
Due to the far-reaching effects of the RAAS pathway, therapeutic manipulation of 
this pathway is very important in treating hypertension and heart failure. ACE inhibitors 
and ATIl receptor blockers are used to decrease arterial pressure, ventricular after-Ioad, 
blood volume and hence ventricular preload, as weIl as to inhibit or reverse cardiac and 
vascular hypertrophy. 
Figure 6 - Components of the RAAS system and their main effects on the cardiovascular system 
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Renin catalyzes the cleavage of angiotensinogen into the inactive angiotensin I, which is 
subsequently converted to the active hormone angiotensin II by both ACE and chymase. ACE also 
degrades bradykinin into inactive fragments, preventing bradykinin induced increases in the 
vasodilators NO and Prostacyclin. Most known effects of Angiotensin II are due to the activation of 
two of the Angiotensin II receptors, namely AT! and ATz (19). 
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Table 3- Physiologie actions of angiotensin II 
Vaseular Vasoconstriction - increased total peripheral resistance by direct actions 
on the contractile elements via enhancement of norepinephrine release 
from nerve terminaIs innervating the blood vessels, increased 
sympathetic discharge, increased medulIary epinephrine release 
Remodeling - enhanced migration; proliferation and hypertrophy of 
vascular smooth muscle celIs, cardiomyocytes and fibroblasts; 
increased matrix formation; indirect stimulation of cardiomyocyte 
proliferation and hypertrophy by theincreased cardiac afterload due to 
volume eXj)ansion secondary to sodium retenti on 
RenaI/ Adrenal Antinatriuresis - prevention of the excretion of excessive amounts of 
sodium in the urine; direct proximal tubule effect to stimulate sodium 
reabsorption and indirect effect via stimulation of aldosterone release 
and subsequent sodium reabsorption in distal tubule. 
Hemodynamic - renal vasoconstriction; increased renal sympathetic 
tone 
Brain Sympathostimulation and attentuation of the baroreceptor reflex 
Dipsogenesis - Thirst Stimulation 
Stimulation of salt appetite 
Stimulation of vasopressin and oxytocin secretion 
Pituitary Synergism with corticotropin-releasing hormone adrenocorticotropin 
Gland secretion 
1.5.2.1.2 Adrenergic and Dopaminaerigic Receptors and Actions 
NE and epinephrine (EP) are endogenous catecholamines released by the 
postganglionic sympathetic nerve terminaIs and the adrenal gland. They interact with celI 
surface receptor molecules in various target organs. This interaction starts a cascade of 
membrane and intracellular events, which result in altered cellular activity (Figure 7). 
Adrenergic receptors and dopaminergic receptors are coupled to G proteins and activate 
cells through alterations in intercelIular calcium, cyclic nucleotides, inositol phosphates, 
and protein phosphorylation. The activation of adrenergic receptors increases HR and the 
strength of cardiac contraction, and causes cardiac and vascular hypertrophy, 
bronchodilation, vasoconstriction, sedation, and analgesia. Adrenergic receptor inhibition 
results in vasodilation, decreased heart rate, and strength of contraction and relaxation of 
prostate smooth muscle. AlI these actions are important in the treatment of diseases such as 
hypertension, congestive heart failure, and angina. 
J 
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The three endogenous catecholamines in humans, NE, EP and dopamine act as the 
chemical effectors of the SNS, adrenomedullary hormonal system and DOPA-dopamine 
autocrine / paracrine system. AlI three systems play important roles in tonic and phasic 
cardiovascular regulation. 
Figure 7 - Physiological Effects of Norepinephrine and Epinephrine 
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NE and EP increase heart 
rate, blood pressure and 
peripheral vasoconstriction. 
Syrnpathetic adrenergic nerves are found in the heart where they innervate the 
sinoatrial and atrioventricular nodes, conduction pathways, and myocytes. Sympathetic 
adrenergic fibers are also found innervating arteries and veins in the peripheral vasculature. 
These adrenergic nerves release NE, which binds to specific receptors in the target tissue. 
Parasympathetic cholinergic nerves derived from the vagus nerves also innervate the heart. 
Acetylcholine (ACh) released by these fibers binds to muscarinic receptors in the target 
tissue. The vasculature in sorne organs of the body is innervated by either parasympathetic 
cholinergic fibers or by sympathetic cholinergic fibers. These nerves release ACh, which 
binds to muscarinic receptors on the smooth muscle and/or endothelium. 
In the heart, NE released by sympathetic nerves preferentially binds to 
adrenoceptors causing positive inotropy, chronotropy, and dromotropy. In blood vessels, 
NE binds adrenoceptors to cause smooth muscle contraction and vasoconstriction. (Figure 
7) NE can also bind to adrenoceptors, which causes vasodilation (this can be observed 
during alpha adrenoceptor blockade), Circulating EP binds to the adrenoceptors to cause 
vasodilation in sorne organs. NE regulates its own release by stimulating adrenoceptors, 
which inhibit its release, or inhibiting other adrenoceptors, which facilitate its release. 
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In the heart, ACh is released by cholinergie nerves, which bind to a cholinergie 
receptor (M2 muscarinic receptor). This produces negative inotropy, chronotropy, and 
dromotropy in the heart. Prejunctional M2 receptor activation inhibits NE release and is one 
mechanism by which vagal stimulation overrides sympathetic stimulation in the heart. In 
blood vessels, M2 receptors on the vascular endothelium are coupled to the formation of 
nitric oxide (NO), which causes vasodilation; however, ACh causes smooth muscle 
contraction through a smooth muscle M3 receptor wh en formation of NO is blocked. 
Sympathetic cholinergie nerves that release ACh and cause vasodilation innervate sorne 
arterial blood vessels, for example in skeletal muscle. Neurotransmitter binding to the 
adrenergic and cholinergie receptors activates signal transduction pathways that cause the 
observed changes in cardiac and vascular function. Drugs are available for blocking 
adrenergic and cholinergie receptors. For example, beta-blockers are used in the treatment 
of angina, hypertension, arrhythmias, and heart failure. Alpha-blockers are used in treating 
hypertension( 19). 
1.5.3.1.3 Vasopressin (Antidiuretic Hormone) 
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Figure 8 - Vasopressin release 
and physiological efTects 
Vasopressin is released from the pituitary due to stimulation by ATII, 
hyperosmolarity, decreased atrial receptor firing and sympathetic stimulation. 
Vasopressin release results in vasoconstriction, which increases BP and renal fluid 
reabsorption, increasing blood volume, which in turn increases BP. 
Diagram from Klabunde, R.E. Cardiovascular physiology concepts (2005) (95) 
Vasopressin (AVP), also known as antidiuretic hormone, is a peptide hormone 
formed in the hypothalamus, then transported via axons to the posterior pituitary and 
released from there. A VP has two principal sites of action: the kidney and the blood 
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vessels. The primary function of A VP in the body is to regulate extracellular fluid volume 
by affecting renal handling of water. It is also a vasoconstrictor and vasopressor agent. 
AVP acts on renal collecting ducts to increase water permeability, which leads to decreased 
urine formation. This increases blood volume, CO and arterial pressure. A secondary 
function of A VP is vasoconstriction. A VP binds to receptors on vascular smooth muscle to 
cause vasoconstriction via the inositol phosphate-3 signal transduction pathway, which 
increases arterial pressure. The normal physiological concentrations of A VP are below its 
vasoactive range. In severe hypovolemic shock, when AYP release is very high, A VP 
contributes to the compensatory increase in SVR (Figure 8). 
There are several mechanisms regulating the release of A VP. Hypovolemia, du ring 
hemorrhage and dehydration, results in a decrease in atrial pressure. Cardiopulmonary 
baroreceptors within the atrial walls and large veins entering the atria decrease their firing 
rate when there is a faH in atrial pressure. Afferent nerve fibers from these receptors 
synapse within the nucleus tractus solitarius (NTS) of the medulla, which sends fibers to 
the hypothalamus, a region of the brain that controls A VP release by the pituitary. Atrial 
receptor firing normally inhibits the release of A VP by the posterior pituitary. With 
hypovolemia or decreased central venous pressure, the decreased firing of atrial stretch 
receptors leads to an increase in A VP release. Hypotension, which decreases arterial 
baroreceptor firing and enhances sympathetic activity, increases AVP release. In 
dehydration, hypothalamic osmoreceptors sense extracellular osmolarity and stimulate 
A VP release when osmolarity rises. A Til receptors located in a region of the hypothalamus 
regulate A VP release, so an increase in ATII simulates A VP release.(30) 
1.5.2.1.4 Nitric Oxide 
Though nitric oxide (NO) is not itself a hormone,we include it here because it acts 
similarly to a hormone in BP regulation. 
Nitric oxide (NO) is produced by vascular endothelium, smooth muscle, cardiac 
muscle and many other cell types. The substrate for NO is L-arginine that is transported 
into the ceU. When acted upon by nitric oxide synthase (NOS), NO and citrulline are 
formed. There are two general forms of NOS: constitutive NOS (cNOS) and inducible NOS 
(iNOS). NO is continuously produced by cNOS. The cNOS found in endothelial cells is 
a1so referred as eNOS. The activity of cNOS is modulated by calcium that is released from 
subsarcolemmal storage sites in response to the binding of certain ligands to their receptors. 
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Substances such as acetylcholine, bradykinin, histamine, insulin, and substance P stimulate 
NO production by this mechanism. Another important mechanism regulating the release of 
NO is shearing forces acting on the luminal surface of the vascular endothelium. By this 
mechanism, increased flow velocity stimulates calcium release and increased cNOS 
activity. Thé inducible form of NOS (iNOS) is stimulated by the actions of cytokines (e.g., 
tumour necrosis factor, interleukins) and bacterial endotoxins (e.g., lipopolysaccharide). 
Induction of iNOS occurs over several hours and results in NO production that may be 
more than a thousand-fold greater than that produced by cNOS. The induction ofiNOS is 
an important mechanism in the pathogenesis of inflammation. 
Nitric oxide serves many important functions in the cardiovascular system. It is 
implicated in vasodilation (ligand mediated and flow dependent), in the inhibition of 
vasoconstrictor influences (e.g., inhibits ATH and sympathetic vasoconstriction), in the 
inhibition ofplatelet adhesion to the vascular endothelium (anti-thrombotic), and in the 
inhibition ofleukocyte adhesion to vascular endothelium (anti-inflarnmatory). It is 
antiproliferative (e.g., it inhibits smooth muscle hyperplasia foIlowing vascular injury) and 
it is a scavenging superoxide anion (anti-inflarnmatory). 
The mechanism ofmany ofthese actions of NO involves the formation of cGMP. 
When NO is formed by an endothelial cell, it readily diffuses out of the ceIl and into 
adjacent smooth muscle ceIls where it binds to a heme moiety on guanylyl cyclase and 
activates this enzyme to produce cyclic guanosine monophosphate (cGMP) from guano sine 
triphosphate. Increased cGMP activates a kinase that subsequently leads to the inhibition of 
calcium influx into the smooth muscle ceIl, and decreased calcium-calmodulin stimulation 
ofmyosin light chain kinase. This in tum decreases the phosphorylation ofmyosin light 
chains, thereby decreasing smooth muscle tension development and causing vasodilation. 
The anti-platelet aggregatory effects of NO are also related to the increase in cGMP. Drugs 
that inhibit the breakdown of cGMP (inhibitors of cGMP-dependent phosphodiesterase 
su ch as sildenafil or Viagra) potentiate the effects ofNO-mediated actions on the target 
cel 1. 
Damage to the vascular endothelium or dysfunctional vasocontriction result in 
impaired NO production. This decrease in NO production leads to platelet aggregation and 
and adhesion leading to thrombosis, as well as upregulation of leukocyte and endothelial 
adhesion molecules. AlI these conditions lead to enhanced inflammation. 
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Hypertension, obesity, dyslipidemias (particularly hypercholesterolemia and 
hypertriglyceridemia), diabetes (both type 1 and II), heart failure, atherosclerosis, cigarette 
smoking, aging, and vascular injury are associated with endothelial dysfunction and 
reduced NO production and availability(2,32,95, 124, 161). 
1.5.2.1.5 Atrial and Brain Natriuretic Peptides 
Atriai natriuretic peptide (ANP) is a 28-amino acid peptide that is synthesized, 
stored, and released by atrial myocytes in response to atrial distension, angiotensin II 
stimulation, endothelin, and beta-adrenoceptor mediated sympathetic stimulation. 
Therefore, elevated levels of ANP are found during hypervolemic states (elevated blood 
volume) and congestive heart failure. ANP is first synthesized and stored in cardiac 
myocytes as prepro-ANP, which is then cleaved to pro-ANP and finally to ANP, the 
biologically active peptide. 
Figure 9 - Atrial and Brain Natriuretic Peptides release and 
physiological effects 
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Diagram from Klabunde, R.E. Cardiovascular physiology concepts (2005) (95) 
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A second natriuretic peptide (brain natriuretic peptide; BNP) is a 32-amino acid 
peptide that is synthesized within the ventricles as well as in the brain (where it was first 
identified). BNP is first synthesized as prepro-BNP, which is then cleaved to pro-BNP and 
finally to BNP. BNP is released by the same mechanisms that release ANP, and it has 
similar physiological actions. Proteolysis ofpro-BNP (108 amino acids) results in BNP (32 
amino acids) together with the N-terminal piece ofpro-BNP (76 amino acids). 
Natriuretic peptides are involved in the long-term regulation of sodium and water 
balance, blood volume and BP. ANP and BNP decrease aldosterone release in the adrenal 
cortex. They increase glomerular filtration rate (GFR), produces natriuresis and diuresis 
(potassium sparing). They also decrease renin release, thereby decreasing the level of A TIL 
These actions contribute to reductions in blood volume and therefore central venous 
pressure, CO, and arterial BP. Chronic elevation ofnatriuretic peptides appears to decrease 
arterial BP primarily by decreasing SVR. Natriuretic peptides released by the heart serve as 
a counter-regulatory system for the RAAS (Figure 9)(2,95,124). 
1.5.2.1.6 Endothelial Mechanisms and Endothelin 
Various blood-bome agents in contact with vascular endothelial cells cause the 
production and release of endothelial factors that elicit contraction or relaxation of vascular 
smooth muscle. Capillary endothelial cells possess the capacity to deactivate substances 
such as prostaglandin, serotonin and bradykinin( 67). They can also convert A TI to 
ATII(67). Endothelial factors therefore modulate the effects of NE released by sympathetic 
nerves as weIl as the effects of tissue metabolites and humoral factors. The three most 
important endothelial-derived substances are: NO, endothelin (ET -1), and prostacyclin. NO 
and prostacyclin act as vasodilators, whereas ET-l serves as a vasoconstrictor. 
ET-l activation causes hypertrophy in small arteries and promotes vascular fibrosis. 
ATH is a stimulant ofET-l production. ET-l production is enhanced in part because of 
endothelial damage, hypertension, oxidized low-density lipoprotein cholesterol and 
increased oxidative stress. AIl ofthese processes contribute to the progression ofvascular 
disease and atherosclerosis. Damage to the vascular endothelium due to atherosclerotic 
processes or following ischemia and reperfusion alters the formation and release of 
endothelial factors. When endothelial damage occurs, the endothelium pro duces less NO 
and prostacyclin, which causes the adrenergic vasoconstrictor tone to be unopposed. This 
can lead to increased vascular tone and vasospasm. Furthermore, decreased production of 
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both ofthese endothelial factors can lead to increased platelet adhesion and aggregation, 
leading to enhanced thrombogenesis. The role of ET -1 in the pathophysiology of 
hypertension is still unclear. ET-l may play either a vasorelaxant role or a vasoconstrictor 
role in different vascular beds in normotension and in mild hypertension. In moderate to 
severe hypertension, enhanced expression ofET-1 produces a predominant vasoconstrictor 
effect associated with enhanced growth of the vascular wall, which contributes to further 
elevation ofBP and to complications of hypertension. 
ET-l release is stimulated by ATH, ADH, thrombin, cytokines, reactive oxygen 
species, and shearing forces which act upon the vascular endothelium. ET -1 release is 
inhibited by prostacyclin and by ANP, as well as by NO. ET-l stimulates aldosterone 
secretion, produces positive inotropy and chronotropy in the heart, decreases renal blood 
flowand GFR, and releases ANP. ET-l has been implicated in the pathogenesis of 
hypertension, vasospasm, and heart failure. ET -1, which is synthesized by vascular 
endothelium, is a powerful vasoconstrictor substance. Vascular smooth muscle contraction 
is observed at concentrations as low as 10-11 M. An endothelin precursor (big ET -1 or pro-
ET-l; 39 amino acids) is cleaved to ET-l (21 ami no acids) by an endothelin-converting 
enzyme found on the endothelial cell membrane 
ET -1 can then bind to ET A receptors found on adjacent vascular smooth muscle 
ceUs leading to calcium mobilization and smooth muscle contraction. The ETA receptor is 
coupled to a G-protein linked to phospholipase-C and the formation ofinositol phosphate 3. 
There are also ETB receptors located on the vascular smooth muscle, which also produce 
contraction. Furthermore, ET-l can bind to ETB receptors located on the vascular 
endothelium, which stimulate the formation NO by the endothelial nitric oxide synthase. 
This ET -1-stimulated release of NO appears to modulate the ET A receptor-mediated 
contraction of the vascular smooth muscle. When ET-l is administered intravenously, there 
is a transient hypotensive response due to NO release, followed by a prolonged 
hypertensive response due to ET-! acting on smooth muscle ETA and ETB receptors. NO 
also inhibits the formation ofET-l.(2,27,95) 
1.5.2.1. 7 Arachidonic Acid Metabolites 
Endothelium, smooth muscle, leukocytes, platelets and parenchymal ceUs are aIl 
capable of producing a variety of vasoactive substances that are products of arachidonic 
acid metabolism. Among these are prostaglandins, prostacyclin, leukotrienes, and 
thromboxanes. These substances are either vasodilators or vasoconstrictors, among their 
many other biological activities. 
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Membrane phospholipids, acted upon by phospholipase A2 or C, form arachidonic 
acid, which serves as the precursor for prostaglandins, prostacyclin, and thromboxanes. 
These are derived from the cyclooxygenase (COX) pathway. COX is an important enzyme 
that is inhibited by aspirin and non-steroidal anti-inflammatory drugs. There are two 
important isoforms of COX: COX-l and COX-2. The COX cyclo-endoperoxoide products, 
PGG2 and PGH2, are acted upon by thromboxane synthase within platelets or prostacyclin 
synthase within the endothelium to form thromboxanes or prostacyclin, respectively. 
The enzyme, 5-lipoxygenase also acts upon arachidonic acid. This occurs primarily 
in leukocytes, to form leukotrienes. Prostacyclin plays an important role in vascular 
function because, like NO, it inhibits platelet adhesion to the vascular endothelium and is a 
strong vasodilator. Damaged endothelial cells do not produce prostacyclin, thereby making 
the vessel more susceptible to thrombosis and vasospasm. Thromboxanes and leukotrienes 
produce vasoconstriction and are important modulators of vascular function during tissue 
injury and inflammation. Prostaglandins have a vascular role during inflammation, and also 
play a subtler role in normal flow regulation, most notably as modulators of other control 
mechanisms. Prostaglandins have both vasoconstrictor and vasodilator activities. 
Leukotrienes and prostaglandins can also make the vascular endothelium more "leaky" 
thereby promoting edema during inflammation(2). 
1.5.2.1.8 Kinins 
Kinins are blood plasma proteins that influence smooth muscle contractions. They 
affect BP, especially during hypotension. They increase blood flow throughout the body by 
increasing the permeability of small capillaries, and by stimulating pain receptors. Kinins, 
bradykinin in particular, are produced by the action of kallikrein upon kininogenm itself 
released from glandular tissue by Ach. Kinins cause increased capillary permeability and 
venous constriction, along with arterial vasodilation in specific organs. The vasodilator 
effects ofbradykinin are thought to be particularly potent because it is one of the rare 
stimuli that elicits the activation of the three most important endothelium-derived 
vasodilator autacoids, NO, prostacyclin, and the endothelium-derived hyperpolarizing 
factor(54) .ACE degrades bradykinin into inactive fragments, thereby preventing 
bradykinin-induced increases in the vasodilators. 
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1.6. Anti-hypertensive drugs 
Sympatholytic drugs can block the sympathetic adrenergic system at three different 
levels. First, peripheral sympatholytic drugs such as alpha- and beta-receptor antagonists 
block the influence of norepinephrine at the effector organ (heart or blood vessel). Second, 
there are ganglionic blockers that block impulse transmission at the sympathetic ganglia. 
Third, there are drugs that block sympathetic activity within the brain. These latter are 
called centrally acting sympatholytic drugs(19). 
Neurotransmission within the sympathetic and parasympathetic ganglia involves the 
release of acetylcholine from preganglionic efferent nerves, which binds to nicotinic 
receptors on the cell bodies of postganglionic efferent nerves. Ganglionic blockers inhibit 
autonomic activity by interfering with neurotransmission within autonomic ganglia. This 
reduces sympathetic outflow to the heart thereby decreasing CO by decreasing heart rate 
and contractility. Reduced sympathetic output to the vasculature decreases sympathetic 
vascular tone, which causes vasodilation and reduced systemic vascular resistance, which 
decreases arterial pressure. Ganglionic blockers also reduce parasympathetic outflow(27). 
Chapter 2 
The Search for Genes Causing Hypertension 
2. 1 Quantitative Traits 
A phenotype can be classified into two different types of traits: qualitative and 
quantitative traits. A qualitative trait has a phenotype that falls into discrete categories, 
which are not necessarily ordered. Blood type is a good example of a qualitative trait. The 
environ ment has very little influence on the phenotype ofthese traits. 
A quantitative trait is polygenetic: it is the sum of several small effects caused by 
several genes. An example is an animal' s metabolism, which is under the influence of many 
different genes. There are three types of quantitative traits: threshold, meristic and 
continuous. 
Threshold traits have only two possible phenotypes, but are multifactorial. It is 
inherited quantitatively, but is expressed qualitatively. When a certain threshold is crossed, 
the phenotype wiII jump onto another IeveI, passing from one category to another. The 
inheritance of such a trait is polygenetic, but the only thing that can be recorded is whether 
the given phenotype appears. There are no in between phenotypes in a threshold trait: it is 
inherited quantitatively, but expressed qualitatively. An example of a threshold trait is 
schizophrenia. 
Meristic traits are discrete: their expression involves a variation in sorne 
characteristic whole number. Examples include fish scale number and hair number. Rare in 
humans, they are often studied in plants and animaIs, such as fish and flies. 
Continuous quantitative traits vary continuously along a measurement scale, and are 
often weIl described by a normal (bell-shaped) curve. In sorne cases, the phenotype values 
do not follow a normal distribution, even though the trait has a polygenetic inheritance. For 
a continous quantitative trait, the phenotype is measured on a linear or quantitative scale. 
Multiple genes control su ch a trait. The environment, to a degree, can also affect these 
traits. They show a continuous spectrum of variation from low to high values in the general 
population. Many human phenotypes su ch as IQ, leaming ability, height, weight, skin color 
and BP are continous quantitative traits. 
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A quantitative trait locus (QTL) is a location on a chromosome or a gene that is 
thought to regulate an organism's phenotype for a quantitative trait. QTL analysis is a way 
of searching for the answers to questions such as: Which genes influence the expression of 
a given quantitative trait? Where are they located on the chromosomes? What is the 
function of each gene and what is its level of influence on the trait? The investigation of 
QTLs requires accurate phenotypic, pedigree and genotypic data from a large number of 
individuals. 
2.1.1 BP as a Quantitative Trait 
BP is a quantitative trait since it varies continuously. Like most quantitative traits, 
BP differences result from the contributions of many genes, including direct contributions 
and interactions of different genes, and environmental effects. 
2.1.2 Studying Quantitative Traits 
Many common diseases and traits such as BP aggregate in families but do not 
segregate as Mendelian traits. This indicates a cornplex pattern of inheritance, with a 
significant influence from environmental factors. Familial aggregation can be due to shared 
genes, shared environments or both. Studies among twins are methods used for assessing 
diseases that aggreagate in farnilies. 
In humans, twin studies are a common way of providing a quantitative assessment 
of the genetic component of a trait. Monozygotic twins share identical genornes while 
dizygotic twins share, on average, half of their genomes, greater sirnilarity of monozygotic 
compared to dizygotic twins is evidence for a possible genetic cornponent for a trait. 
Estimates ofheritability can be derived from other kinds ofrelationships too. Heritability is 
strictly population-and phenotype-specific. By selecting individu ais with rare phenotypes, 
for example, one can " enhance" heritability for greater genetic control. Further resources 
for studying the genetic contribution of a trait are, adoptees, immigrants, genetically 
isolated populations, and native cultures, which may totally lack sorne environmental risk 
factors such as a low salt diet. Another way of studying the genetic contribution to a trait is 
to use animal models, including inbred strains. 
The prevalence of essential hypertension is 3.8 times greater in individuals with a 
positive farnily history of hypertension, suggesting that hypertension has a genetic 
component (180). Studies using twins show that the BP correlation is higher in 
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monozygotic twins than in dizygotic twins(7, 111). However, ev en in monozygotic twins, 
BP variation is sufficiently large that a substantial "environment" effect has been 
implicated. The environmental factors, such as diet and stress, significantly affect BP 
variation among individuals (74). A differential response ofBP to dietary salt intake has 
been demonstrated in the pathogenesis of hypertension. Sorne individuals respond to an 
increase in dietary sodium intake with an increase in BP and manifest a decrease in BP with 
salt restriction while other individuals show little or no change in BP, suggesting that a 
genetic heterogeneity may account for the difference in the etiology of essential 
hypertension (193-195). 
2.2 Strategies for Searching for Genes of Comp/ex Traits 
A straightforward way to analyze whether a gene predisposes an individual to a 
disease would be to analyze its sequence, from several affected individuals and look for 
variants associated with the disease. Given the limitations of CUITent sequencing methods, 
the large number of genes and the high co st involved, this method is not practical. There are 
four common types of methods for this analysis: linkage analysis, allele-sharing methods, 
association analyses and studies using model organisms (lOS). Mapping methods, such as 
linkage analysis often take advantage of cell division processes such as meiosis. 
2.2.1 Mapping 
Two types ofmaps can be used to describe a genome: genetic maps, which are 
derived from recombination frequencies between genetic markers; and physical maps, 
which are constructed from information about the physicallocation of genes on 
chromosomes. Genetic mapping takes advantage of genetic markers. A genetic marker is a 
segment of DNA with an identifiable physicallocation on a chromosome whose inheritance 
can be followed. It may be possible to align the two types of maps if they share markers. 
2.2.1.1 Genetic Maps 
Linkage is the tendency of two markers on the same parental chromosome to be 
passed on together, in contrast to markers on different chromosomes, or far apart on the 
same chromosome, behaving independently at meiosis. The amount ofrecombination 
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between two gene loci vary widely, and the recombination percentage between two loci is 
related to how far apart they are physically. 
The technique for genetic mapping is therefore to mate parents differing in two or 
more traits (that is, having different alleles at two or more loci) and then to score the 
patterns of segregation of parental alleles among the offspring. Two genes on different 
chromosomes will segregate randomly at meiosis, so that a quarter of the offspring will 
show each of four combinations of alleles at the two loci. However, if the genes are close 
together on the same chromosome, parental combinations of alleles will pass to the 
offspring together, unless they are separated by recombination. The probability of 
recombination increases as the physical distance between genes increases, so the 
recombinant percentage of the progeny provides a measure of the genes' relative distance 
apart. 
If the parents differ at three or more loci, recombination between them is additive, 
allowing for multiple recombination. This allows the three loci to be placed in a "linkage 
group," a linear array in which recombination percentages represent the relative distances 
between the loci. A map can be built up in stages from different crosses.The linkage group 
describes the gene order along a whole chromosome. 
Linkage maps depend entirely on the availability of polymorphisms--the existence 
of two or more alleles at a locus. This has traditionally been the great limitation of 
mapping, but the availability of highly polymorphie DNA markers has revolutionized 
genetic mapping in many animal species. 
2.2.1.1.1 Homologous Recombination 
In many cases, genes on the same chromosome that are inherited together produce 
offspring with unexpected allele combinations. This results from a process called crossing 
over or homologous recombination. Sometimes at the beginning of meiosis, a chromosome 
pair (one chromosome from the mother and one from the father) may intertwine and 
exchange sections or fragments of a chromosome. The pair then breaks apart to form two 
chromosomes with a new combination of genes that differs from the combination supplied 
by the parents. Through this process of recom bining genes, organisms can produce 
offspring with new combinations of maternaI and paternal traits that may contribute to or 
enhance survival. 
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Homologous recombination is the process by which two chromosomes, paired up 
during prophase 1 ofmeiosis, exchange a distal portion oftheir DNA. Crossover occurs 
when two chromosomes, normally two homologous pairs of the same chromosome, break 
and then reconnect, each to the end piece of the other. Ifthey break at the same place or 
locus in the sequence of base pairs, the result is an exchange of genes, called genetic 
recombination. This outcome is the normal way for crossover to occur. Any pair of 
homologous chromosomes may be expected to cross over several times during meiosis, 
depending on the species and on the length of the chromosome. The recombination is 
actively assisted in the cell by machinery that has been weIl conserved through evolution. 
This process reduces the genetic linkage between alleles on the same chromosome and 
increases the genetic variation within a population. Because there is sorne crossing over of 
DNA when the chromosomes segregate, it can happen that alleles on the same chromosome 
are separated and go to different cells. There is a greater probability of this happening if the 
alleles are far apart on the chromosome, as in this case it is more likely that a crossover will 
occur between them. The relative distance between two genes can be calculated using the 
offspring of an organism showing two linked genetic traits or markers, and finding the 
percentage of the offspring for which the two traits are not together. The higher the 
percentage of descendants not exhibiting both traits, the further apart on the chromosome 
the two traits will be. 
2.2.1.2 Genetic Markers 
A genetic marker is defined as a segment of DNA whose physical location on a 
chromosome is known and whose inheritance can be followed. A genetic marker can have a 
function and thus be a gene or it can be a section ofDNA with no known function. 
Eukaryotic DNA contains very short simple sequence repeats, called micro satellites 
throughout the genome that can be used as markers. Microsatellite markers are inherited 
following a codominant pattern and a variation in the number of repeats between 
individuals is frequent (179). This variation in repeat number makes them useful for 
genotyping. These markers can be amplified by polymerase chain reaction (PCR) using 
primers specifie to their unique flanking DNA and typed on polyacrlyamide sequencing 
gels or agarose gel electrophoresis. 
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To align genetic markers along the chromosomes and to determine the distance 
between them, different mapping techniques are available. These include linkage, radiation 
hybrid (RH) and physical mapping. 
2.2.1.3 Linkage Analysis 
Among individuals of an experimental population or species, sorne phenotypes or 
traits occur randomly with respect to one another. This situation is known as independent 
assortment. An exception to independent assortment, called linkage develops when genes 
appear the same chromosome. Such genes tend to be inherited together in genetic crosses, 
because they are part of a single chromosome that is passed along as a unit. Thus they are 
said to be linked genes. Linkage analysis is the study of linkage between genes. It is 
valuable in gene-hunting and genetic testing. 
Because DNA segments that lie near each other on a chromosome tend to be 
inherited together, markers are often used as tools for tracking the inheritance pattern of a 
gene that has not yet been identified but whose approximate location is known. The 
statistical estimate of whether two loci are likely to lie near each other on a chromosome 
and are therefore likely to be inherited together is called the LOD score. A LOD score of 3 
or more is generally taken to indicate that the twq loci are linked and are close to one 
another, since it indicates a likelihood ofless than 1 in 1000 of observing the result if the 
two loci are not linked. 
The rate of crossing over between linked genes differs. The crossover frequency 
indicates the distance separating genes on the chromosome. Greater the distance between 
linked genes, greater the chance will be, for the non-sister chromatids to crossover or 
recombine, in the region between the genes. By working out the number of recombinants it 
is possible to obtain a measure for the distance between the genes. This distance is called a 
genetic map unit, or a centimorgan (cM), and is defined as the distance between genes for 
which one product of meiosis in 100 is recombinant. A linkage map is created by finding 
the map distances between various traits or loci that are present on the same chromosome. 
ldeally one avoids having significant gaps between traits to reduce the possibility of 
multiple recombination events, which would decrease the accuracy of the map. 
Linkage mapping is critical for identifYing the location of genes that cause genetic 
diseases. In a normal population, genetic traits and markers will occur in aU possible 
combinations, with the frequencies of combinations determined by the frequencies ofthe 
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individual genes. A linkage map is a chromosome map of a species or experimental 
population that shows the position of its known genes and/or markers relative to each other, 
rather than as specific physical points on each chromosome. Tt is not a physical map of the 
chromosome. 
A genetic map is a map based on the frequencies of recombination between markers 
during crossover of homo logo us chromosomes. 
Linkage analysis determines the position of a gene in relation to the known 
positions of particular genetic landmarks. It establishes links between known genetic 
markers and unknown genes. Linkage mapping of QTL in organisms amenable to 
inbreeding begins by choosing parental inbred strains that are genetically variable for the 
trait of interest, with filial generations, FI and F2. Usually the parent strains will have 
different mean values for the trait, but this is not necessary, as two strains with the same 
mean phenotypic value can vary genetically owing to complementary patterns of positive 
and negative QTL allelic effects. A mapping population is then derived by back-crossing 
the FI progeny to one or both parents, mating the FI together to create an F2 population, or 
constructing recombinant inbred lines by breeding several generations ofF2 sublines up to 
homozygosity. These methods are very efficient for detecting marker-trait associations. By 
successively reducing the size of the region exhibiting linkage with the QTL ultimately to a 
single gene, by the process described above, one obtains a hight resolution map. Given a 
high-density polymorphic molecular marker map spanning the interval in which the QTL is 
located and a population of recombinant genotypes with breakpoints between adjacent 
markers, it is a simple matter in principle to define the QTL position relative to a pair of 
flanking markers. The challenge posed for high-resolution QTL mapping is that individual 
QTLs for BP are expected to have small effects on phenotype that are sensitive to the 
environment. 
2.2.1.4 Statistics: The LOD Score 
The LOD score is an efficient statistic for evaluating pedigrees for linkage. Given a 
certain pedigree inc1uding recombinants, it is possible to calculate the overalllikelihood of 
the pedigree on the alternate assumptions that the loci are linked (recombination fraction = 
0) or not linked (recombination fraction = 0.5). The ratio ofthese two likelihoods gives the 
odds of linkage and the logarithm of the odds is the LOD score. 
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The LOD score is usually calculated by computer programs such as 
MAPMAKER( 114). A LOD scores of + 3 is generally taken as the threshold between 
linkage and exclusion. A positive LOD gives evidence in favor of linkage, while a negative 
LOD is evidence against linkage. LOD score analysis is a powerful method for scanning 
the genome to locate a disease gene. Its weaknesses include vulnerability to error, problems 
with locus heterogeneity and limits on the ultimate resolution achievable, together with the 
need to specify a precise genetic model, detailing the mode of inheritance, gene frequencies 
and penetrance of each genotype. 
It has been proposed (l 05, 167)that a series ofthreshold criteria be used when 
attempting to find linkage for complex diseases. The different thresholds are described as 
suggestive linkage, significant linkage, highly suggestive linkage, and confirmed linkage. 
2.2.2 Physical Maps 
Genes may be assigned to physical positions within chromosomes or chromosome 
regions by somatic cell genetics and radiation hybrid mapping. 
Somatic cell genetics was developed in the 1970s. This method does not require a 
breeding colony, or ev en a live animal, as long as cell samples are available. Nor does it 
require polymorphic markers, since somatic cell genetics, uses interspecific variation. 
However, it has low-resolution. Somatic cell genetics simply establishes synteny groups 
and assigns them to a chromosome, but does not specify position or order. 
Somatic cell genetic analysis uses viable hybrid cells derived from the fusion of 
somatic cells from different species. It depends on the observation that chromosomes are 
lost from only one of the two parental sets. For example, rat-hamster hybrids segregate rat 
chromosomes, so that it is possible to derive a hybrid panel uniquely representing each rat 
chromosome. Hybrids all retain and express the full set of hamster genes; however, a 
hybrid will retain and express only the rat genes on the particular rat chromosomes retained 
in that hybrid. Thus, by detecting patterns of presence and absence of rat markers in a set of 
hybrids and correlating these with the patterns of the presence or absence ofparticular 
chromosomes, it is possible to assign a rat gene to a particular rat chromosome. Sorne 
regional mapping is possible using hybrids that retain only portions of a chromosome. 
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2.2.2.1 Radiation Hybrid Mapping 
The use of radiation hybrids (RH) and RH maps has revolutionized physical 
mapping of disease loci in humans. It is a simple approach: in a single 96-weU PCR plate 
one can map a candidate gene with relatively high resolution. RH mapping is an extension 
of regional, physical mapping. Hybrids are constructed from donor cells (cells from the 
species to be mapped or ceU hybrids bearing a single chromosome of the species to be 
mapped) that have been lethaUy irradiated to cause chromosome fragmentation. The 
hybrids therefore contain only smaU regions of the irradiated donor genome incorporated 
into chromosomes of the unirradiated parent. These radiation hybrids are more likely to 
bear two genes if the genes question are physicaUy close together on a chromosome, so the 
frequency of concordance ofmarkers may be used as a measure oftheir physical proximity. 
The construction of a rat RH map is of great significance because the rat has been, 
and continues to be, utilized as a powerful model system for investigating human 
physiological and genetic diseases, particularly multifactorial diseases. Rat ceUs carrying a 
selectable marker are irradiated with a dose ofX-rays to fragment their chromosomes; the 
irradiated ceUs are fused with hamster cells, and a panel of fusants is selected using the rat-
derived marker. These celllines carry random fragments ofrat DNA integrated into the 
hamster chromosomes. Any particular fusion line carries only a sm aU fraction of the entire 
rat genome. As a result, genes, which lie relatively close to each other in the rat genome, 
tend to be found simultaneously in the same fusion ceU line, much more often than 
expected by chance. The frequency of co-occurrence is a measure of the physical distance 
between the two genes. Relative frequencies of co-occurrence can be used to order sets of 
three genes as weIl. 
RH mapping can be simply done by performing PCR. Radiation hybrids, which 
have marker-related sequences, are revealed by the hybridization ofDNA molecular 
markers to an array ofDNAs from the panel of fusants. Molecular markers for 
hybridization may also be cosmid, BAC, or similar clones, rather than specific genes. In 
this case, radiation hybrid mapping may be used to determine non-overlapping regions 
called contigs. Markers need not be polymorphic in the rat, as long as they are 
distinguishable from hamster homologs. 
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2.2.2.2 Physical Mapping Using Genome Sequences 
The draft sequences for human, mouse and rat genomes have been published. This 
has facilitated the mapping of markers. It is possible to locate the genetic markers by 
blasting their sequence on each genomic sequence. The maps obtained provide the physical 
position of a marker and the distances are measured in base pairs (bp). 
Physical maps using genome sequences are not based on a pattern of inheritance 
like the linkage maps. They include polymorphic and non-polymorphic markers. Since the 
distances are given in base pairs, it provides a more accurate estimate of the relative 
position of the markers and the distance separating them. 
2.2.3 Co-segregation analysis 
Co-segregation analysis is used to identify loci related to the phenotype, in this case, 
BP regulation. It is based on the principle that the frequency of recombination between two 
given loci is dependent on the physical distance that separates them. In order to perfonn a 
co-segregation analysis, first, there must be a linkage map of the genome of the species 
being studied. Second, there must be a good method available to measure how BP varies 
among animaIs. A breeding experiment is then conducted mating animaIs, whose BPs have 
been measured and genotyped. Using a computer program, the variation in BP is correlated 
with each marker. Considering one family in a breeding experiment (a male, female and 
their offspring), if the BP is always high with a certain sequence of a marker and always 
low with another sequence, then the gene for BP regulation is close to the first marker on 
the chromosome. If the variation in the BP is more or less random in relation to the marker, 
then there is little or no linkage between BP and that chromosomallocation. The level of 
association between BP and chromosomallocation is called an "LOD" score. The higher 
the LOD score, the more "important" a gene may be in regulating BP. These chromosomal 
locations probably do not code directly for BP, but instead for factors which shape the BP. 
Co-segregation analyses provide a statistical assessment of the probability that a marker is 
inherited in conjunction with the BP phenotype because the two loci are physically close or 
by chance only. BP is not the only example to which this analysis can apply.As long as 
there is a definite phenotype that can be observed, co-segregation analysis can be applied to 
locate the chromosomallocations of the genes that regulate that phenotype. 
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Knowing which chromosomallocations are important enables genetic 
manipulations of the key genes affecting the regulation ofthe trait to be tracked. The other 
possible outcome of locating a QTL is being able to identify the gene influencing the BP 
and the regulation of its expression. 
2.2.4 Candidate gene approach 
Genes considered to affect the risk of contracting a given disorder due to their 
function, expression or presumed interaction with a disease-causing gene, are cal1ed 
candidate genes. The majority of studies on the genetics of complex diseases are carried out 
by analyzing candidate genes. At present, we know only of a partiallist of genes associated 
with the cardiovascular system, to say nothing oftheir variations. It has been estimated that 
there are 15000-30000 genes that are expressed in any given cell ofthe cardiovascular 
system(72). AIso, the large variation of genes in the population is an obstacle to the design 
and interpretation of disease-association studies. Although candidate gene studies are 
potentially useful in the determination of predisposing genes, at present they face many 
problems. The use of candidate gene method does not allow for the discovery of novel 
genes. 
2.2.5 Animal models 
Using animal models allows the knowledge of systems to be extrapolated to other 
species. New animal models are continually being identified and developed to evaluate the 
pathogenic mechanisms (28,79), diagnostic (156) and therapeutic procedures (73,106), 
nutrition (52), metabolic disease, and the efficacy ofnovel drug development (26). 
To be successful, a genetic animal model should be inbred (homozygous throughout 
the genome) so as to reduce heterogeneity in terms of genetics and etiology. It should be 
physiologically and pathologically well characterized. It should display sorne 
characteristics of the clinical picture. Finally it shouid also be amenable to biochemical, 
physiological, pharmacological, and genetic studies. 
In order for the results obtained to be significant and valid, so that conclusions 
about the disease being studied can be drawn are accurate, it is also critical to select a 
suitable animal. 
Small animaIs provide significant advantages in modeling human diseases. 
Environmental factors oflaboratory animaIs can be controlled. The litters are large, 
inbreeding is a possible technique, and relevant tissue sampI es are available more easily 
than from humans. AIso, since the time of development and lifespan is much shorter for 
such animaIs, the animal models al10w for longitudinal measurements of variables and 
multi-generation pedigrees are easily produced. 
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Usually, one uses various crosses ofinbred strains expressing the phenotype 
differently, and the progeny are then genotyped to find the loci linked to the trait. Once the 
predisposing genes have been identified, transgenic rats or mice will provide the final proof 
for the biological significance ofthese genes. However, the farther apart evolutionally, the 
two species compared are, the more caution must be exercised in generalizing from one to 
the other. 
Thus it is important to consider wh ether animal data is useful for understanding 
corresponding conditions in humans. A good animal model 1) shares a homologous region 
ofthe genome with at least a subset of human patients, 2) enables the analysis of a complex 
multifactorial disease into single gene regions and 3) enables the rapid assessment of 
physiology, biochemistry and pharmacology. 
With reference to hypertension in particular, experimental nongenetic approaches 
have resulted in development of extremely useful models that allow studying the effects of 
induced hypertension on end-organ damage in different species. These approaches include 
surgically induced hypertension, as shown in the Goldblatt experiment, which introduced 
the first animal model of hypertension in dogs evoked by unilateral constriction of the renal 
artery (29,109,118). Surgical induction of hypertension has been studied in rats, rabbits, 
dogs, pigs(108,109,20S), monkeys(118) and mice. In the phenotype-driven experimental 
approach, takes advantage of the natural variation among inbred strains and crosses to find 
quantitative traits and determine which genes are responsible for them (182). In contrast, in 
a genotype-driven approach, a known gene is studied with genetically based interventions 
(over-expressions or ablation) and is characterized. 
Naturally occurring animal models of a disease can be extremely useful in 
providing new biological insights into a given phenotype. There are many advantages in the 
use of animal models in studies. 
To use animal models in the study of hypertension, one must understand: (102) 
1. The manner in which the hypertensive strains and their normotensive controls have 
been derived. 
2. The number of major genes that may be contributing to the hypertension. 
3. The genetic relationship between the hypertensive strains and their nonnotensive 
counterparts and the limitations of inter-strain comparisons for investigating 
mechanisms of hypertension (173). 
4. The genetic homogeneity of the experimental strains. 
5. The principles behind the development and use of specialized congenic strains. 
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For hypertension, the most widely used animal for studies is the rat, not mouse as in 
most other diseases. The reason for this is simple. It is much harder to measure the BP of a 
mouse. For atheroscerosis, mice, rabbits, and dogs are often used. 
2.2.5.1 Development of the Rat Model 
Historically the laboratory rat, Rattus norvegicus was the first mammalian species to 
be domesticated for scientific research(69). The first genetic studies focused on the 
inheritance of coat colour. 
For mammalian geneticists, the mouse eventually became the model of choice 
because of its smaller size, which simplified housing requirements, also because it is 
smaUer and quicker to breed, and thus easier to manipulate genetically. There are also many 
mouse strains with varying coat col ours, together with other mouse mutants with 
Mendelian patterns of inheritance that had been collected by mouse fanciers(132,133). 
Unfortunately for the present research, a good inbred mouse model of hypertension 
has not yet been developed. Furthennore, the gene knockout and overexpression 
approaches for which the mouse is very useful cannot be applied to the discovery of 
naturally occurring genes that produce hypertension. Although mice are of great use in 
identifying the action of given genes and for validating the importance of a candidate gene, 
these approaches cannot be used for finding genetic variants or pathways that can lead to 
hypertension(25). 
Rat strains were developed primarily by physiologists and other biomedical 
researchers in their own laboratories, and were selected and bred to have traits of 
biomedical interest. Many oftheses strains were inbred. They are generated by systematic 
inbreeding, which fixes certain alleles in a strain so that they replace all other alleles 
present in an outbred population. Rat research has had a different focus to that of mouse 
research, being more physiological in nature: the rat provides unique opportunities for 
disease research that can be integrated with the resources generated by the Rat and Human 
Genome Projects. Hence, researchers have created more than 234 inbred strains of rat by 
selective breeding. This has'fixed' disease alleles in particular strains, for disorders that 
range from hypertension to urological defects(69). Hence, the rat is used in biomedical 
research such as physiology, experimental medicine and drug development. 
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The rat became the third mammal to have its genome sequenced(69), after mice and 
humans. This genome sequence enables researchers to view the genomic evolution of the 
rat compared to that of the mouse and the human (69). The rat genome, being 2.75 
gigabases (Gb) is smaller than the human genome, which is 2.9 Gb, but appears to be larger 
than the mouse, which is variously evaluated to be between 2.5 and 2.6 Gb. Most of the 
human genes associated with disease have orthologues in the rat genome( 69). 
The knowledge of the rat genome sequence allows for the direct comparison of rat 
and human orthologues. The effects of inheritance on disease phenotypes can be easily 
pursued in both species and the identification of QTLs and complex trait differences that 
are involved in disease processes can be pursued accurately(69). 
Combined physiological and genomic information should lead to the development 
of better pre-clinical models of human disease, which will aid in the development of new 
therapeutics. The rat was chosen as the animal model due to the wealth of physiological and 
pharmacological data for the rat. The knowledge of the genome sequence of the rat should 
facilitate the discovery ofmammalian genes that are involved in disease.(69) 
2.2.5.2 The Rat as an Animal Model in the Study of Hypertension 
Considering the tendency for essential hypertension to run in families, it is logical to 
create a model using selection to obtain an experimental model resembling as closely as 
possible the human hypertensive patient. This approach consists of identifYing among 
randomly bred animaIs, the ones displaying higher arterial pressure values, and breeding 
them over subsequent generations until the BP of the descendant population is found to be 
consistently elevated. At the same time, descendants of from the original parents showing 
lower BP values are also bred to develop normotensive progeny. This strategy has been 
widely used in "traditional" models of genetically determined experimental hypertension. 
Inbreeding models of hypertension are frequently used to study mechanisms ofBP 
control, to test and develop anti-hypertensive drugs and to investigate the pathogenesis of 
spontaneous hypertension. (102) The formaI definition of an inbred strain is: a set of 
animaIs that is produced by at least 20 consecutive generations of parent crossed with 
offspring mating that can be traced to a single ancestral pair in the 20th subsequent 
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generation. AnimaIs of an inbred strain are nearly fully homozygous, thus providing a well-
defined and consistent genotype for analysis. 
The most commonly used method to develop the inbred experimental models is as 
follows. The BP of a large number of non-inbred animaIs is measured. Using this 
information, one selectively breeds those having the highest BP. In each successive 
generation, the offspring with the highest BP are interbred (i.e. brother crossed with sister) 
to produce an inbred strain. After 20 generations ofbrother-sister mating, the offspring 
should be homozygous at >99% of loci, and therefore all animaIs within the strain should 
be highly inbred and near isogenic (genetically identical). 
The most commonly used traditional inbred genetic models of hypertension include 
the Milan hypertensive rat, the Lyon hypertensive rat, the New Zealand genetically 
hypertensive rat, the Sabra hypertensive rat, the Dahl Salt-Sensitive hypertensive rat (S) 
and the Spontaneously hypertensive rat. With these models, substantial progress has been 
made in identifYing physiological, biochemical and environmental factors that can affect 
BP. Very less progress has been made in identifYing primary genetic determinants of 
hypertension. 
Any hypertensive strain, in order to be studied, must have normotensive 'control' 
strains for comparison. Most normotensive or control strains' progenitors have been 
derived from the same colony of animaIs as the model hypertensive strain, in the hope that 
the control rats would be genetically very similar to the hypertensive rats. Selection of the 
hypertensive strain is established by the selective inbreeding of offspring with the highest 
BP. The normotensive strain is established by the selective inbreeding of offspring with 
relatively normal or even low BP. Although a hypertensive strain and its traditional 
corresponding normotensive control strain may be traced back to the same colony, the 
animaIs in the original colony were genetically diverse, and differed with respect to alleles 
at multiple loci, not just those affecting BP. Thus during the process of selection and 
inbreeding of the hypertensive and normotensive strains, alleles that were unrelated to BP 
could randomly be fixed in the homozygous state. Depending on the variety of alleles 
present in the original breeding colony, the hypertensive strain and the normotensive 
control strain could fix different alleles at many loci simply by chance. As a consequence of 
genetic drift, the hypertensive strain and the normotensive strains end up differing with 
respect to multiple loci throughout the entire genome, not just in those affecting BP. 
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Therefore, one can detect differences between the hypertensive strains and their 
corresponding nonnotensive controls with respect to a large number ofmolecular, 
physiological and biochemical characteristics. The presence of a given trait or 
polymorphism in a nonnotensive strain does not exclude the possible involvement ofthat 
trait or polymorphism in the pathogenesis of hypertension. ln a nonnotensive strain the 
capacity of certain alleles to promote hypertension may be counterbalanced by other alleles 
that tend to lower BP. lt is evident that there are limitations to traditional models due to this 
approach, due to potentially incomplete genetic homogeneity and the effect of gepetic drift. 
Generally, in most phenotype driven models, hypertension is associated with high BP, 
cardiac hypertrophy, endothelial dysfunction and renal functional impainnent (proteinuria, 
decreased creatinine clearance). The outcomes seem to depend on the underlying origin, 
genetic background, and possibly species differences, as weIl as on the degree of 
hypertension. The phenotypic characteristics and pathophysiology ofrats carrying 
spontaneous or genetically engineered mutations are most often attributed to alterations in 
the modified gene. But the 'genetic background' defined as a collection of aIl genes present 
in an organism that influence a trait or traits and the surrounding environment are factors 
that can significantly affect the observed phenotype. So it is important ta consider these 
epigenetic and extragenetic factors when using rats to study complex diseases. The use of 
strains with a uniform genetic background greatly facilitates the interpretation of 
experimental results(50). 
While most of the inbred strains used in hypertension research share a common 
origin, each strain has its own unique set of characteristics or background lesions. Strain 
characteristics are the result of sequence differences in genes (allelic variance) among 
inbred strains. Strain attributes can be the result of single genes or a combination of genes. 
The phenotype of the rat, carrying a modified gene will vary, depending on the genetic 
background.because of the presence of genetic modifiers (allelic variants at loci other than 
the one being genetically modified) in the inbred strain genome. Genetic modifiers may 
function through a number of mechanisms: (1) they can suppress or enhance the expression 
of genes involved in physiological or pathological pathways; (2) they can alter DNA 
transcription rates or mRNA stability; (3) they can have epigenetic effects causing changes 
in DNA methylation or chromatin structure; and (4) they can result from a variation of gene 
copy (103,115,125). Phenotypic differences among different strains carrying the same 
mutation may therefore be the direct result of genetic modifiers that are unlinked to the 
modified gene or allelic variants. 
2.2.5.2.1 The New Zealand Genetically Hypertensive Rat (GH) 
The GH strain was the first selected strain to consistently develop high BP(109). 
The rise in BP in GR compared to its nonnotensive control starts early in life, since it 
shows a higher BP at 2 days of age. In this model the RAAS, fluid and sodium retention 
and salt-sensitivity do not seem to play a major role in the mechanism resulting in 
hypertension(29). 
2.2.5.2.2 The Spontaneously Hypertensive Rat (SHR) 
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The SHR was bred for high BP, without any provocative dietary or environmental 
stimuli( 144), and is a strictly inbred strain. In terms of end-organ damage, many SHR rats 
develop cardiac hypertrophy and progress to heart failure between the age of eighteen and 
twenty-four months. Despite the uniformity of the model, not aIl the rats exhibit signs of 
heart failure after twenty-four months, showing that there may exist individual differences 
seen amongst the rats in the model(109,139). The model allows for a wide variety of genes 
to cosegregate and may mimic a subtype of the human primary hypertension that is 
inherited in a Mendelian fashion. The genetic mechanisms implicated in the hypertension 
of SHR have been attributed to both neural and vascular alterations( 118). 
2.2.5.2.3 The Dahl Salt-Sensitive Hypertensive Rat (S) 
In 1960 Lewis K Dahl and coworkers( 4, 143,145)selectively bred rats for 
susceptibility (8 rats) or resistance (R rats) to the hypertensive effect ofhigh- salt diet (8% 
Sodium Chloride (NaCl)). This model was developed after the observation that 
consumption of salt resulted in hypertension in sorne individuals whereas others remained 
normotensive despite a high salt diet. He started with 8prague-Dawley stock, and after 
three generations of selective breeding, using 7.3% (NaCI) and L-tridothyronine, an agent 
that accelerates the appearance of salt-induced hypertension, he had successfully separated 
distinct 8 and R lines. In the R line, the level of dietary salt had very little effect on the BP, 
but in the 8 line, increased dietary salt caused a markedly elevated BP. Thus, the two lines 
provided an interesting model for the interaction of an environmental factor (salt) with 
genotype(29). 
52 
GeneraIly, S rats on a high-salt diet develop a fulminant hypertension and are dead 
by 8 weeks oftreatment, while those fed on a low-salt diet (0.3% NaCI) diet survive weIl, 
even though they also develop marked hypertension. It is a corn mon misconception that S 
rats develop high BP only when fed excess salt. The BP rise is much slower in S rats on a 
low salt diet than the S rats fed a high salt diet. BP in R rats remains at a low level and is 
unaffected by dietary salt. S rats on a low-salt diet did consistently have pressures 
significantly higher than R rats fed either high or low salt diets. Inbred S rats are 'salt-
sensitive' in the sense that they develop marked hypertension on low (0.3-4% NaCI) or 
normal (1 %NaCI) salt diets(143). 
The age at which S rats start on a high-salt diet influences BP response. If rats are 
fed a high salt diet at weaning, the ri se is BP is rapid (4,31,143). If salt feeding is delayed 
until 3 months of age, the rise in BP is less rapid. BP in S rats is influenced by dietary 
potassium as weIl as sodium. If dietary sodium is kept constant, BP of S rats is inversely 
related to dietary potassium(59,143) . On diets with different absolute concentrations of 
NaCI and KCI, but with identical Na/K molar ratios, S rats on the higher absolute NaCI 
intake have higher BP, Thus both the absolu te amount of sodium and the Na/K molar ratios 
are important in determining the final BP. It has been shown that in the S strain, the 
suppression of the sodium-potassium pump is not the cause ofhypertension(135). 
The S rat is more sensitive than the R to hypertension induced by experimental 
procedures other than high dietary salt. These include treatment with deoxycorticosterone, 
cortisone, or adrenal regeneration hypertension, renal artery clipping, injection of cadmium 
and psychological stress. Thus, the selective breeding of rats for one form of hypertension 
has apparently influenced their sensitivity to many forms of experimentally induced 
hypertension(29). 
Inheritance ofBP characteristics in S and R rats is polygenic. This means that genes 
at several genetic loci influence BP. Cross-transplantation ofkidneys between Sand R rats 
has a significant effect on the BP of the recipient animal. An S kidney transplanted into an 
R rat increases BP, whereas a R kidney transplanted into an S rat decreases BP. Thus, the 
kidney mediates part of the genetic predisposition to hypertension. It has been reported that 
S rats have 15% fewer glomeruli than R rats. Following 20-30 days ofhigh-salt feeding the 
S rats compared to R rats, showed increased single nephron blood flow, increased single 
nephron glomerular filtration rate and decreased resistance at the afferent and afferent 
arteriolar segments(29). 
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In terms of the difference in nervous systems, the S rat has been observed to possess 
reduced baroreceptor sensitivity, due to a neural component of the baroreceptor reflex. 
Basal sympathetic activity and pressor responsiveness to hypothalamic stimulation are 
enhanced in S over R rats. Renal al and a2-receptor concentrations were higher in S than 
in R rats, and high-salt feeding caused an increase in renal a2-receptors in S but not in R 
rats. 
In terms ofhemodynamic parameters, when rats were placed on a high salt-diet (8% 
NaCI), after 3 days R rats showed an 18% increase in CO, a 14% decrease in peripheral 
resistance and no change in BP. At 7 days of salt feeding, the CO and peripheral resistance 
in R rats were back to the levels seen in control rats on a 0.3% NaCl diet, while BP 
remained unchanged. S rats responded with a 10% increase in CO, a 10% increase in 
peripheral resistance and a 20% increase in BP after 3 days on a high salt diet. At 7 days on 
high salt, CO had retumed to the control value, but BP and peripheral resistance remained 
elevated. 
Salt feeding significantly increased aortic prostaglandin 12 synthesis in S but not in 
R rats. Exercise has a pronounced effect on the BP response of S rats to salt feeding. If 
exercise, such as running, is started soon after weaning, salt-induced hypertension is 
delayed and mortality is reduced. 
In S rats, hypertension may be related to decreased availability of vasodilatory NO 
leading to increased vasoconstrictive response to norepinephrine and A TIL The high-salt-
induced decrease in NO availability and vascular relaxation could be due to inhibition of 
NO synthase or increased superoxide production. This is supported by reports (87)that 
arginase inhibition restores arterial endothelial function in S rats with salt-sensitive 
hypertension (29). 
In essence the S rat share many of the phenotypic traits commonly found in 
hypertensive humans. Like many hypertensive humans, the S rats are salt sensitive, are 
hyperlipidemic, are insulin resistant, have reduced renal function, have blunted pressure 
natriuresis and exhibit low renin hypertension. 
2.2.5.2.4 The Milan Hypertenive Rat (MHS) 
The MHS rat is mainly characterized by an increase in renal sodium reabsoption, 
related to mutations in the gene that codes for adducin, a skeletal protein involved in 
transepithelial sodium transport. It is of interest mainly because of the genetic link between 
adducin polymorphisms and primary hypertension as seen in sorne hypertensive 
patients(10). 
2.2.5.2.5 The Lyon Hypertensive Rat (LH) 
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In this inbred strain, low-renin hypertension has been implicated, because it shows 
hypersensitivity of preglomerular vessels to ATIl( 166). 
2.2.5.2.6 The Sabra Hypertensive Rat (SBH) 
The SBH strain exhibits gender specific quantitative trait loci for salt susceptibility 
on chromosome 1 (20 1). 
2.2.5.3 Advantages of using the Rat as a Genetic Model in Hypertension 
Human essential hypertension is a complex disease, so researchers have selectively 
bred rats for hig BP to provide animal models for the disease. Table 4 summarizes the 
reasons for the use of the rat as a model for human hypertension by pointing out the 
limitations and difficulties of studying the genetic factors controlling hypertension in the 
human population(92, 1 04). 
Table 4- Advantages of the rat as a model for genetic hypertension 
Characteristics Inbred rats Humans 
Herita bility of ~60% 30-40% 
hypertension 
Environmental factors Controllable Uncontrollable 
Onset of hypertension Earlyage Advanced age 
Genetic homogeneity High (inbred) Low (outbred) 
Reproducibility of BP Relatively good Relatively poor 
measurements 
Analytical approaches QTL mapping in Linkage analysis (e.g., affected 
experimental crosses sib-pair) 
Development of congenic Association study (unrelated 
strains subjects) 
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2.2.5.4 Rat Chromosomes of S Implicated in BP Control 
Previously published studies that looked for linkage to BP using genetically 
hypertensive S rats and norrnotensive rats have yielded many putative quantitative trait loci 
(QTL) for BP on aU rat chromosomes except chromosomes 4, Il, 14, 19,20, X and Y 
(144). Table 5 describes and lists the various QTLs found on the S rat chromosomes. 
Table 5- BP QTLs localized in the Dahl salt sensitive rat 
Contrasting Number Confirmed Rat by Normotensive of Reference Features Chromosome Strain QTLs Congenic Strains 
1 LEW 3 Yes (59,86,162) 
WKY 3 Yes (35,36,39,61 ) Interacting with Chr. 
2 MNS 2 Yes (35,39,44,45) 10 QTLs(l47) 
LEW 1 No (59) 
3 R 2 Yes 
(21,107) 
LEW 2 Yes (59,134) 
5 LEW 2 Yes (34,59,62,159) 
6 BN 10 No (126) Linkage study 
7 R 1 Yes (22,24,63) Il ~-hydroxylase 
might be the QTL 
8 LEW 2 Yes (6) Current study 
9 R 1 Yes (60,122,146) 
MNS 2 Yes 3 QTLs are epistatic to 10 LEW 4 Yes (37,39,43,65) one another, while 4
th 
QTL is additive (18) 
12 WKY 1 No (92) 
13 R 1 Yes (85,204) BN 1 Yes (177) 
15 WKY 1 No (33,34) 
16 LEW 1 Yes (59,127,128) BN 1 Yes (121) 
17 LEW 1 In dispute (34,59) 
18 LEW 1 No (59) BN 1 Yes (121,177) 
Table 5 is based on Deng 2005 (38). 
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2.3 Previous Studies on Rat Chromosome 8 
In a linkage study in 1995, Schork (168)and coworkers conducted a linkage study in 
a F2 population originating from a cross between an SHR and a Brown Norway rat. They 
mapped a BP QTL where the SHR alleles increased BP. It had a significant LOD score of 
5.1 at chromosome 8. 
Independently in 1995, Takami and colleagues found a locus for the peroxisomal3 
keto-acyl CoA thiolase on chromosome 8 cosegregated with BP in crosses involving SHR 
and DahVIwai salt-sensitive rats (184). Peroxisomal3 keto-acyl CoA thiolase is involved in 
the last reaction of the ~-oxidation cycle.1t is involved in the thiolytic cleavage of3-
ketoacyl-CoA to acetyl-CoA, resulting in an acyl-CoA shortened by two carbon atoms. In 
Takami's study, it was found that the locus located on rat chromosome 8 had a hypotensive 
effect. 
In 1996, Kren et al. established a congenic strain in which the gene for polydactyly-
luxate syndrome (Lx) was used to move a region on chromosome 8 from Brown-Norway 
rats (BN) to the SHR background (97-100). The resulting congenic strain had a BP that was 
20 mmHg lower than that of SHR(99). This demonstrated the existence of a QTL on 
chromosome 8. 
In a linkage study in 1998, using F2 generations derived from LEW and S, Garrett 
et al. (59) mapped a BP QTL to rat chromosome 8 (Figure 10). The statistical LOD score 
was two, which meant that it barely reached suggestive statistical significance. 
Figure 10 - LOD score and QTL location-Garrett 1998 
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Later in 2000, Garret et al. (64) in another linkage study using F2 generations 
derived from the two hypertensive strains, the S and the SHR, in an attempt to find QTLs 
that differentiate these two hypertensive strains. They localized a QTL on chromosome 8, 
which also attained LOD scores that are considered suggestive for linkage to BP (Figure 
Il). In this case, the Salleles increased BP. 
In 2002, Khan et al. (94), using the congenic strain established by Kren, found a 
nicotinie receptor gene cluster on rat chromosome 8 implicated in nociceptive and BP 
hyper-responsiveness. 
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Nociception is the reception of a noxious stimulus. Pain is a potential outcome of 
nociception. Nociception occurs in the receptor portion of afferents and the action 
potentials are conveyed to the spinal cord via afferent axons. Nociception is relayed to the 
brainstem, hypothalamus and thalamus via tract cells or neurons. In the case of pain, 
nociception is relayed to the thalamus via neospinothalamic and paleospinothalamic tract 
cells or neurons. From the thalamus, certain thalamacortical fibers project to the limbic 
system, where the feeling ofhurt or pain is generated. Nociception can also, activate 
generalized autonomie responses independently of the relay ofpain to conscious levels 
causing pallor, sweating, bradycardia, a drop in BP, subjective faintness, nausea and 
syncope. 
Ali nociceptors are free nerve endings that have their œil bodies outside the spinal 
column in the dorsal root ganglion and are named based upon their appearance at their 
sensory ends. There are mechanical, thermal, and chemical nociceptors. They are found in 
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skin and on internaI surfaces such as periosteum and joint surfaces. Deep internaI surfaces 
are only weakly supplied with pain receptors and will propagate sensations of chronic, 
aching pain if tissue damage in the se areas occurs. 
There is a relationship between BP and acute pain sensitivity. Research on the 
hypoalgesia associated with hypertension has highlighted the importance of inter-
relationships between the cardiovascular and pain regulatory systems(203). Even in the 
absence of clinical hypertension, familial risk for hypertension in healthy individuals 
appears to be associated with diminished responsiveness to acute pain, apart from the 
influence of actual BP levels. There is suggestive evidence that these effects are mediated 
in part by elevated central descending pain inhibitory activity. Although the se studies might 
suggest that BP-related hypoalgesia is specifically associated with central mechanisms 
contributing to hypertension risk, other studies have demonstrated that regardless of 
hypertension status, elevated of the resting BP level is associated with decreased pain 
sensitivity in healthy normotensive individuals. 
The relationship between resting BP and pain sensitivity arises from the "central 
autonomic network", a group of integrated brain regions that coordinate responses to 
environmental stimuli. The brain regions underlying control of the cardiovascular system 
are known to overlap substantially with those contributing to antinociception. In particular, 
the nucleus tractus solitarius (NTS), which serves as the interface between autonomic and 
sensory systems, participates in pain regulatory pathways, as evidenced by the fact that 
stimulation of the NTS induces antinociception. 
The NTS is located at the first synapse in the baroreceptor reflex pathway. It plays 
an important role in the processing of visceral information, receiving major afferent input 
from both the vagus nerve (subserving the baroreflex) and spinallaminae involved in 
nociceptive processing. Antinociception elicited by activation of the NTS may derive in 
part from its direct and indirect efferent projections to the periaqueductal gray and other 
brain structures, such as the nucleus raphe magnus and rostral ventrolateral medulla, that 
are known to be involved in modulation of pain pathways. In addition to the brain regions 
mentioned, efferent projections from the NTS to the AS nuclei and A6 nuclei, also known 
as the locus coeruleus of the medulla, may be important contributors to BP-related 
antinociception, given that direct stimulation of these regions elicits analgesia. 
Interconnections between the NTS and the locus coeruleus may be particularly important in 
mediating nonopioid analgesia, given that the locus coeruleus is a primary source of 
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noradrenergic neurons in the neuraxis. Pathways from the NTS to spinal cord nuclei 
modulating cardiovascular tone, including sympathetic and parasympathetic preganglionic 
nuclei, also interact with descending pain modulation pathways. Thus, through a 
baroreceptor feedback loop, descending pain inhibitory pathways may be able to self-
regulate their activity through actions in autonomic centers of the spinal cord modulating 
cardiovascular function(12). 
A model ofthe relationship between BP and pain sensitivity has been proposed. 
According to this model, baroreceptor activation has a role in the relationship between 
resting BP and acute pain sensitivity. According to the model, pain, through a 
somatosensory reflex, increases sympathetic arousal thereby increasing BP. This increase in 
BP leads to increased baroreceptor stimulation, which in tum triggers decreasing pain 
inhibitory activity, thereby helping to retum arousallevels to astate ofhomeostasis. 
Persistent baroreceptor stimulation related to BP elevation lasting from a few minutes to a 
few days may result in a resetting ofbaroreceptors. It is believed that this situation 
increases the BP set point around which the baroreflex is centered and thus elevating the 
BP threshold required to trigger baroreceptor activation (12) . 
In 2002, Ueno et al. (190) carried out an acute pharmacogenetic analysis in an F2 
generation, derived from Prague hypertensive-hypertriglyceridemic rats and LEW rats. 
They found a BP QTL on chromosome 8, with a significant LOD score of 7.0 after the 
blockade of the sympathetic nervous system using pentolinium. Sympathetic blockade of 
blood vessels causes vasodilation and hypotension. Pentolinium acts as a ganglionic 
blocking agent and inhibits the release of adrenaline and noradrenaline from adrenergic 
nerves. In addition, pentolinium binds to the nicotinic acetylcholine receptor. This receptor 
is penneable to a range of divalent cations including calcium. The influx of calcium may 
activate a potassium ion cUITent, which hyperpolarizes the cell membrane. Blockage of the 
receptor leads to smooth muscle relaxation and vasodilaton. 
Chapter 3 
Experimental Methods Used to Study Rat Chromosome 8 
3. 1 Objective of My Study 
According to previous studies, rat chromosome 8 (C8) likely contains a BP 
QTL(59). The purpose of the present study is to provide strong evidence that such a QTL 
exists. Previously, linkage analysis ofa population ofrats, in which F2 (SxL) were bred 
together had provided statistically suggested evidence of the presence ofleast one QTL in 
chromosome 8. Of course, linkage analysis is prone to false positives since it is based on 
probability, not on certainty. So to demonstrate conclusively that the chromosome region 
truly contains a BP QTL, a more stringent genetic test must be applied. If a QTL does in 
fact exist, we also want to map it to a precise chromosomal region. The final goal of this 
study is to identify the effect of this QTL on BP. 
3.2 Materials and Methods 
3.2.1.Rat Strains Used-Dahl Salt -Sensitive vs. Salt-Resistant Rats 
The Dahl S strain is used as the salt sensitive hypertensive strain in this study. 
Although the R strain is usually compared and contrasted with the S strain, using the R 
strain generally impedes genetic mapping. Since both S and R strains are derived from the 
same stock, their genomes are quite similar. So polymorphisms among chromosome 
markers capable of differentiating S from R are rare (about 29%). So we used a 
normotensive strain derived from a different originator stock to facilitate genetic mapping. 
3.2.2 Lewis Strain 
Bred by Dr. Margaret Lewis, this strain originated from Wistar stock. The Lewis 
strain (LEW) has low BP whether it is fed a high salt diet or a low salt diet. It is a 
normotensive strain. The rate of polymorphisms among chromosome markers capable of 
differentiating S from LEW is about 50%. 
3.2.3 Strategies used in the Study of the Rat Model 
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To prove that a chromosome region truly con tains a BP QTL, it is useful to breed 
congenic strains. A congenic strain provides a definite genetic test. We bred congenic 
strains for chromosome 8 by crossing the S strain with the Lewis strain. The effect ofthis 
cross is to replace a region of chromosome 8 on the S strain rat with the homologous region 
of the L strain rat. Thus, congenic strains permit the association of changes in BP with a 
specific region of the chromosome. 
3.2.4 Congenic Strains 
A major limitation of existing animal models of hypertension is that hypertensive 
strains differ from normotensive control strains in multiple regions of the genome, notjust 
in regions that contain genes regulating BP( 1 02). With the availability of simple methods to 
detect DNA polymorphisms, it has become possible to create hypertensive strains that are 
genetically identical to comparable normotensive strains except in selected chromosome 
regions. 
The development of congenic strains is a very powerful analytical tool who se 
purpose is to transfer a mutation or a chromosomal segment from rats of one inbred genetic 
background to another (Figure 12). 
Strains that are genetically identical except for a single chromosomal segment are 
said to be congenic. Tü produce congenic animal models, one first backcrosses the donor 
inbred strain with the recipient inbred strain at least 8 to 10 times. At every generation, one 
selects for the locus or chromosomal region to be transferred. After 8 to 10 backcrosses, the 
only region ofthe genome that originates from the donor strain is the single segment 
containing the selected locus. At this stage, heterozygous rats are intercrossed to produce 
rats homozygous for the introgressed region. Although this process is long, it yields closely 
related inbred strains that differ in only one small region oftheir genomes. Later we will 
discuss a more sophisticated protocol, called "speed congenics," that shortens the 
generation time by counterselecting the alleles from the donor strain(31 , 129). 
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If congenic strains exhibit a difference in BP, one may draw the conclusions that a 
locus affecting BP exists within the differential chromosome segment. Systematic studies 
can then be performed to investigate further the physiological, biochemical and molecular 
mechanisms that contribute to the strain differences in BP. The size of the differential 
chromosome segment can be reduced by molecular selection techniques and by continued 
backcross breeding. 
It may be possible to have multiple congenic 'controls' for a single hypertensive 
strain, where each congenic control differs from the hypertensive parental strain with 
respect to a specific region of the genome. In addition to providing evidence for the 
existence ofBP regulatory loci in restricted chromosome regions, the congenic strains can 
be used to study how different portions of the genome interact to affect BP, permitting for 
example, the differentiation between individual effects oftwo interacting chromosomes and 
their combined effect. 
It is expected that each congenic strain, will have lower BP compared with the S 
strain, because the regions introgressed should all contain the minus BP QTL allele derived 
from the normotensive strain. 
Figure 12 - The Congenic 
Finally resulting 
m: 
2 3 4 5 6 7 8 
If the region replaced 
contains a BP QTL , 
the congenic is 
expected ta have a 
lower BP than the S 
rat. 
9 10 
11 12 13 14 15 16 17 18 19 20 X 
Figure 13 - Speed Congenic-
Strategy to Construct a Congenic 
RECIPIENT (S) 
F1 BC1 BC2 BCS CONGENIC 
........ ............................... ~ •.. ................. 
~~~U ~ 
Backcrossing to the recipient strain Brother -Sister 
mating 
DONOR(LEW) 
3.2.4.1 Baekerossing and Speed Congenies 
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A process of whole genome marker assisted selection called "speed congenics" can 
accelerate the development of congenic strains. Assuming one has genotyped the whole 
genome, one selects the breeders that, besides containing the target region of the donor, 
have a greater proportion of alleles from the recipient strain throughout the genome (Figure 
13). The rats chosen as backcrossing breeders should preferably be male, since the male can 
be paired with many females of the receiver genome. One screens the polymorphic genetic 
markers covering the entire background of the genome to select male offspring with the 
fewest donor alleles in their background. This produces the congenic strain more 
efficienctly. Using the 'best' male in the next round ofbreeding, in this way, dramatically 
reduces the time taken to c1ear the background of the recipient strain. If 60 background 
markers spaced on average 25 cM, are used to screen males at each generation, it is 
calculated that by four backcross generations the donor genome contamination would be 
less than 1 %. With this method, developing a congenic strain is reduced from 4-5 years to 
2-3 years, reducing the breeding time by a factor of 2 since only 5 backcross generations 
are needed for the genetic composition of the congenic rat to be more than 99% from the 
recipient and less than 1 % from the donor strain (Figure 14). The only drawback of the 
method is the cost oftyping the many markers needed. 
1 TRADITIONAL 
1 Recipient 
Average % 
heterozygous 
DIR segments 
% Recipient 
genorne 
1 Donor 1 
Congenie 
Diagram based on figure in Functional Genomics in Rodent Models of Hypertension by 
Mcbride et al.. It compares the average % ofheterozygous DIR segments and the % of 
recipient genome that is fixed at each generation ofthe speed congenic method to the 
comparable generation of the traditional method 
Figure 14 - Comparison of Traditional and Speed Congenie Methods 
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3.2.4.1.1 How Chromosome 8 Congenies Strains in this Study were Seleeted. 
The basic scheme for our studies was to put a specific region of chromosome 8 of 
the normotensive strain LEW onto the genetic background of the Dahl S strain, using a 
standard breeding protocol. Dahl S rats were initially crossed to rats ofLEW. FI progeny 
were backcrossed to S to produce the first backcross generation (BCl). BCI rats were 
genotyped for 92 markers, which were evenly spaced throughout the rat genome with an 
average of about 18 cM (see Table 6). The ideal breeder selected and designated for a 
subsequent breeding with an S rat to produce BC2, amongst the BC 1 generation was 
heterozygous, SL, for chromosome 8, but possessed the maximum SS homozygosity for the 
rest of the irrelevant genome. BC2 rats were genotyped and screened exactly as for the BC 1 
rats, to derive an ideal breeder amongst the Be2. This process was repeated for a total of 
five backcrosses, each time choosing rats heterozygous throughout the region of interest as 
breeders for the next backcross. At this point, it was found that only the markers delineating 
a chromosome 8 region of interest were heterozygous SL, whereas the markers for the rest 
of the genome including those flanking the chromosome 8 region of interest were 
homozygous SS. At BC5, two heterozygotes were intercrossed to generate homozygotes. 
This fixed the region of interest of chromosome 8 from the normotensive strain onto the 
background of the S strain. The markers found on Tables 6 and 7, and on Figure 19 were 
used in selecting rats on the basis oftheir genotypes. 
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Table 6 Chromosome Markers used to make congenic Strains 
Chromosome Chromosome Markers Tested 
1 DIWox25-DIRat304-DIMco27-Sa-DIUiaI2-DIArb33-DIRatI9-DIMco4 
2 Camk2d-Gca-D2Rat302-Cpb-D2Mco 13-D2Rat 199-D2 Uia5 
3 1p3Rat 1 07-D3Rat 17-D3Rat24-D3Rat66-D3 Wox3-D3Rat52 
4 1p4Mghl-D4MghI6-D4Uial-D4MitI7-D4Uia4 
5 1p5Rat130-D5Mit5-D5 Uia2-D5Mco34-D5 Uia8-D5 Rat95-D5Mco2-Ela2 
6 1p6Rat l 05-D6Mit I-D6Mgh3 
7 1p7Mghl-D7RatI52-D7Rat44-D7RatlIO-D7Ratl8-D7RatI28-D7Rat115 
8 1p8Mgh11-D8RatI34-D8Rat43-D8Uia2-D8Rat55 
9 1p9Rat64-D9Uia9-D9Wox23 
10 1p10Mco10-D10Mco17-DJOMgh6-DIOWox6-DIOM11Mit58-DIOMco15-
IpIORat1I-DIOM~hl 
11 Ipll Rat50-DII Mitl-DII Uial 
12 1p12Mit6-DI2Rat32-DI2Mit4 
13 Ip13Mgh4-DI3Uia3-DI3Uia8 
14 1p14WoxIO-DI4Uia2-DI4Uial 
15 1p15Uia8-DI5Mgh2-DJ5RatI26 
16 VI6RatI4-DI6Rat67-DI6Uia2-DI6Rat21-DI6Mit2-DI6RatI2 
17 DI7Wox7-DI7Mit5-DI7MghJ-:-Agtr1a-Ednl 
18 DI8Uia6-DI8Mit8-DI8Mco6-DI8Wox 7 
19 DI9Rat82-D19Rat25-DI9Rat57 
20 D20Wox3-D20Woxl-D20Mghl 
X DXUia2-DXMcol-DXRat93 
lAu the markers are polymorphie between Sand LEW strains. Table taken from Deng et 
al. 2002 (127). The rest of the markers are mostly anonymous. 
3.2.5 Genome-wide scanning 
A genome-wide sean is the genotyping ofhundreds ofpolymorphic markers, 
preferably evenly through the genome, in a selected sample of individuals with or without a 
qualitative trait or with a measurable quantitative trait. It is used in situations where certain 
aIl el es for a marker segregate with a phenotype. Through genome-wide seanning, it is 
possible to find novel loci associated with a trait when the research is not biased by 
previous hypotheses ofmoleeular pathogenesis. Usually highly polymorphie repeat markers 
are used, although new DNA-array technology, monitoring thousands of densely spaced 
single nucleotide polymorphie markers, have drawn much attention lately. In order to 
ensure that the strains were not genetieally eontaminated, a rigorous and striet quality 
control procedure was instituted, consisting of genetic monitoring with genome-wide 
markers (Table 6) together with physical discrimination of the rats. 
3.2.6 Choice of Markers: 
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It is essential to maintain the target region ofheterozygous throughout the process 
of producing congenies. The greater the distance between the markers used to monitor the 
genotype, the greater the chance of a double recombination event occuring between the 
markers. The development of congenic lines does not help in constructing genetic maps, 
but it does render them more accurate. 
3.2.7 Microsatellite markers 
The advent ofthe polymerase chain reaction (PCR) has made mapping relatively 
quick and easy. A microsatellite is a DNA sequence containing short sequences repeated in 
tandem arrays. They are usually mono-, di-, tri- and tetranucleotide repeats, repeating on 
the order of lOto 100 times. These euchromatic repeated sequences are scattered 
throughout the non-coding DNA of eukaryotes. They are highly polymorphie in terms of 
length and are use fuI in PCR genotyping. Figure 15 is an example of a microsatellite . 
.. TCCAGACAAGGTGGTGTGTGTGTGTGTGTG 
TGTGTGTGTGTGTTTCTCCAGTGAGATTTA ... 
Figure 15 - Microsatellite example 
In order to make a marker, the region of interest is screened for microsatellites in 
the rat genome sequence given at the NCBI database. The microsatellite and 50 nucleotides 
around it are inputted into a primer selection program such as the Primer3 program(3). 
Using the output from the program, the best set of oligonucleotides is selected based on the 
statistical output for each set of derived prim ers that the program has devised. The new 
marker should be "blasted" in the NCBI database in order to make sure that it is unique to 
the region of interest. If it is unique, then the marker is tested at different temperatures 
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(45°C, 50°C, 55°C, and 60°C) to find the optimal temperature. If the marker is 
polymorphic and specific then it can be used to genotype congenic strains and to place the 
marker on the genetic map based on the genotype that results. Key factors in PCR primer 
design, in order to produce successful amplification of markers are: 
-Seventeen to thirty nucleotides in length 
-GC content ideally about 50% 
-If the GC content is low, a longer primer is preferable in order to avoid low melting 
points. 
-One should avoid primer sequences with long runs of a single nucleotide, with 
significant secondary structure or those that have complementarity between the two 
primers. 
3.3 Sample preparation and DNA analysis 
Polymorphie markers were genotyped by PCR. The PCR reaction mixture 
consisted of 1 X PCR buffer containing 1.5mM MgCb, 200!lM of each of the dNTPs, 11lM 
of each primer, 0.12U Taq DNA Polymerase and 10-200 ng of rat genomic DNA, which 
was extracted by tail biopsy from each rat using Qiagen Genome kit. The genotype of each 
rat was determined by PCR. PCR was initiated at 95 oC for 5 minutes, followed by 30 
cycles of94 oC for 40 cycles, 45°C or 50°C or 55°C or 60°C for 40 seconds depending on 
the marker, noc for 1.5 minutes and ended by 5 minutes of extension at noc. The PCR 
products were analyzed either on a 4% agarose gel or on a 6% nondenaturing 
polyacrylamide gel; depending on the size differences of the products among rat strains of 
interest (please refer section 3.4). 
To obtain PCR products that can be analyzed on a polyacrylamide gel, a PCR 
reaction of 10JlL containing the ingredients that are essentially the same as above, except 
that l)lCi of alpha- Phosphorus-32 label dCTP was added to each PCR reaction sample, 
while reducing the unlabeled dCTP to one tenth ofthat normally used. After PCR, samples 
were loaded on 6% nondenaturing polyacrylamide gel containing 5% glycerol. This was 
run at twenty to thirty watts, at room temperature, until the bromophenol blue dye reached 
the bottom of the gel. PCR products were then scored by autoradiography. 
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3.4 Mo/ecu/ar separations used in this study 
3.4.1 DNA Gel Electrophoresis 
Electrophoresis is a technique used to separate or purify macromolecules, especially 
proteins and nucleic acids, that differ in size, charge or conformation (Figure 16) (192). 
In this technique, one makes a gel with slots in it. The gel itself is composed of 
either agarose or polyacrylamide. Agarose is a polysaccharide extracted from seaweed. It is 
typically used at concentrations of 0.5% to 4%. Higher concentrations of agarose facilitate 
separation of small DNA fragments, while low agarose concentrations allow resolution of 
larger fragments. Agarose gels are easy to prepare; and are also non-toxic. Agarose gels 
have a large range of separation, but relatively low resolving power. By varying the 
concentration of agarose, fragments of DNA from about 200 to 50, 000 bp can be separated 
using standard electrophoretic techniques. 
Finally, the DNA is stained with a fluorescent dye, such as ethidium bromide and 
the gel is examined under ultraviolet illumination. Ethidium bromide is an intercalating 
agent commonly used as a nucleic acid stain for techniques such as this one. When exposed 
to ultraviolet light, it will fluoresce with a red-orange color, which intensifies almost 20-
fold after binding to DNA(192).An unknown DNA fragment can be electrophoresed in 
parallel with commercially bought standard fragments, and its size can be estimated if it 
falls within the range of the standards. 
Polyacrylamide, the other common reagent, is a cross-linked polymer of 
acrylamide. It is toxic. The length of the polymer chains is dictated by the concentration of 
acrylamide used, typically between 3.5% and 20%. Polyacrylamide gels are more difficult 
to prepare than agarose gels. Because oxygen inhibits the polymerization process, the gel 
must be poured between glass plates or cylinders. Polyacrylamide gels have a rather small 
range of separation, but very high resolving power. In the case ofDNA, polyacrylamide is 
used for separating fragments of less than about 500 bp. However, under appropriate 
conditions, fragments of DNA differing in length by a single base pair are easily 
resolved(192). The gel is immersed within an electrophoresis buffer. A small amount of 
DNA is added in a slot and an electric CUITent is run through the gel. The DNA is 
negatively charged because of the phosphates in its backbone, and it migrates towards the 
positive pole at the end of the gel. The gel separates DNA fragments of different sizes due 
to friction: small DNA molecules experience little frictional drag from solvent and gel 
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molecules, so they migrate more rapidly than larger fragments. The result is that the electric 
current will distribute the DNA fragments according to their sizes, the largest near the top, 
and the smallest near the bottom. 
3.4.2 Autoradiography 
To detect the DNA in polyacrylamide gels one uses autoradiography (Figure 17). 
Autoradiography is a means of detecting radioactive compounds with a photographic 
emulsion. The form of emulsion favoured is a piece ofX-ray film. Radioactive tracers 
allow small quantities of substances to be detected, enabling sm ail differences in labeled 
PCR products to be seen. Direct measurement of the minute differences using ultraviolet 
light absorption or by staining with dyes is not possible because the se methods have 
limited. Once radioactive DNA fragments are electrophoresed on a gel, the gel is placed in 
contact with the X-ray film and is left in the dark for a few days. The radioactive emissions 
from the bands ofDNA expose the film. When the film is developed, dark bands appear, 
corresponding to the DNA bands on the gel. To enhance the sensitivity of autoradiography 
an intensifying screen is often used. This screen is coated with a compound that fluoresces 
when it is excited by ~-rays at low temperature. In this study, the ~-rays were produced 
from the radioactive isotope 32p . A radioactive gel is placed on one side of a photographic 
film and the intensifying screen on the other. Sorne ~-rays expose the film directly, but 
others pass through the film and would be lost without the screen. When the high-energy 
electrons strike the screen they cause fluorescence, which is detected by the film(192). 
Figure 16 - DNA gel electrophoresis 
a) 
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DNA migrates 
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a) Scheme of the method: A 
horizontal gel made of agarose ( a 
substance derived from seaweed, 
and the main component of agar). 
The agarose melts at high 
temperature, then gels as it cools. 
A "comb" is inserted in the molten 
agarose; after the gel cools, the 
comb is removed, leaving slots, or 
wells/ lanes(shaded regions). The 
DNA is then placed in the wells and 
an electric CUITent is run through 
the gel. Because the DNA is an 
acid, it is negatively charged at 
neutral pH and electrophoreses or 
+ migrates, towards the positive pole 
This results in that the 
DNA fragments will be distributed 
according to their sizes; the largest 
near the top, the smallest near the 
bottom. The gel is then soaked in a 
fluorescent dye, su ch as ethidium 
bormide (a fluorescent dye which 
stains the DNA) and the gel is 
examined under ultraviolet 
illumination. When exposed to 
ultraviolet light, the dye will 
fluoresce with a red-orange color, 
intensifying almost 2ü-fold after 
binding to DNA. 
b) An unknown DNA can be 
electrophoresed in parallel with 
commercially bought standard 
fragments, and its size can be 
estimated if it falls within the range 
of the standards. A commercially 
bought molecular standard q>X174 
DNA/Hae ID which is loaded 
SIll/lane is pictured here. 
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Figure 17 - Autoradiograpby 
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a) Gel Electrophoresis. 
Electrophorese sm ail radioactive 
DNA fragments in parallellanes on 
a polyacrylamide gel. At this point, 
the DNA bands are invisible (their 
positions are indicated by lines). 
b) Autoradiography. 
Place a piece ofx-ray film in 
contact with the gel and 
intensifying screen. Leave it in a 
cassette in the dark for 3 days at 
-Booe or longer, if the DNA 
fragments are radioactively week. 
Finally, develop the film to see 
where the DNA bands are on the 
gel. 
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3.5 Measuring BP- Telemetry 
Male rats were weaned at 21 days of age, maintained on a low salt diet (0.2% NaCl) 
and then fed a high salt di et (2% NaCl) from 35 days of age until the end of the experiment. 
Telemetry probes were implanted when the rats were 56 days old. The implantation surgery 
involved the following: the rats were anesthetized by the inhalation of isoflurane at a dose 
of 4% for 3 minutes. During the surgery, the state of anesthesia was maintained by 
isoflurane at a dose of 1.5-2%. The pressure catheter, which contained the biocompatible 
gel at the tip and the noncompressible fluid connecting the tip to the pressure sensor, was 
implanted through the femoral artery until it reached aIl the way up to the abdominal aorta. 
It was secured by sutures to the blood vessel. The telemetry device body, which included 
the pressure sensor, the reusable electronics module, and a battery, was fixed to the muscle 
wall and was left in the abdominal cavity. After the surgery, the rats were allowed to 
recuperate for ten to seventeen days. In the first three days of recuperation, the rats were fed 
Jell-O containing the analgesic buprenorphine at 0.5% mg/kg. Afterward, they were given a 
di et of Ensure milkshake with chocolate in addition to the 2% NaCl standard meal. This 
supplement usually lasted up to five days to facilitate their appetite and thus weight gain.At 
the implantation stage, the rats had been on 3 weeks of high salt di et and had body weights 
of 250 to 320g. The telemetry probe implantation procedure is the same for all rats studied 
in our laboratory (44). The Figure 18 describes the timeline for rats chosen to have their 
BPs measured. MAP, DAP, and SAP were measured individually. BP was measured at two 
different times or more, using different litters bom at different times of the year, to exclude 
seasonal and environmental influences. The BP data were pooled from separately 
reproducible measurements for each strain. Once the time- period for BP measurement was 
concluded, the rats were sacrificed. The final body weights of the animaIs were measured, 
and certain organs such as the heart, kidney and brain were harvested for future studies. 
Only male rats were used in this study because in the female BP can vary due to the 
hormones, such as estrogen, involved in estrus. 
Figure 18 - Timeline for data collection 
High Salt Diet 
(2% NaCI) 
Timeline 
Telemetry Starts 
Measured 
Mean Arterial Pressure (MAP) 
Sytsolic Arterial Pressure (SAP) 
Diastolic Arterial Pressure (DAP) 
Only male rats were used. 
1 See text for details. 
3.6 Statistical Approach 
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BP is considered when comparing congenic strains to the S strain. The statistical 
test, ANDVA detects a difference between any of the groups being compared. For BP 
measures, the repeated measures' analysis of variance ANDVA is used, to compare the 
significance level for a difference or a lack of it, between a congenic strain and the control 
S Strain. This form of ANDV A takes into account, that for any given animal, BP is 
measured at several points in time. When the ANDV A detects no significant difference, it 
indicates that there is no significant difference between the groups being compared and no 
further analysis is required. If the ANDV A detects a significant difference, it indicates that 
there is a significant difference between the groups being compared. 
To distinguish which pairs of groups are different, we also perform Dunnett post 
hoc comparison. The Dunnett test takes into account multiple pairwise comparisons to 
" 
determine which congenic strains are different from the control strain S. A probability 
value of p < 0.05 was considered statistically significant. The Dunnett test adjusts the p 
values for differences in sample sizes among the compared groups and multiple 
comparisons. In the analysis, a BP component is compared each day for the period of 
measurement among the strains. We report data as mean ± standard deviation. These 
statistical computations were performed with the SPSS statistical program (1). 
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Chapter 4 
Results 
4. 1 Congenic Strains Produced in My Study 
By following the speed congenic method, two congenic strains were developed 
from hypertensive Dahl salt sensitive S rats and normotensive Lewis (LEW) rats. Using the 
speed congenic method, the congenic strains were developed in five generations instead of 
the eight generations that would have otherwise been required. The chromosome regions 
containing various LEW substitutions in the congenic strains are shown in figure 19. In the 
final congenic strains, the homologous regions of the LEW strain replaced each region of 
interest from the S strain. 
In figure 19, the linkage map, indicated as a grey bar, is essentially the same as 
published previously in a linkage study(142) based on an F2 (S x LEW) population. 
Numbers to the right of the map are units in cM, and to the left of the map are units in 
centiRays (cR) between markers. To locate a marker of interest onto an existing RH 
framework map, the results of genotyping of that marker were entered into the 
RHMAPPER pro gram, available interactively on the website 
http://rgd.mcw.eduIRHMAPSERVER. The solid blue bars symbolize the S chromosome 
fragments that have been replaced by those of the LEW rat. The entire region indicated by 
solid bars and junctions between the solid and shaded bars are homozygous LEW alleles on 
the map for ail the markers listed in the corresponding positions. Shaded bars on the ends of 
solid bars indicate ambiguities of crossover breakpoints between markers. The physical 
map consists of the alignment of rat supercontigs in an ascending order from top to bottom 
on chromosome 8 obtained by blasting a marker to the NCBI database 
(http://www.ncbi.nlm.nih.gov/genome/seqlRnBlast.html). The name of a supercontig starts with NW _047 
followed by three digits. Parenthesized numbers below a supercontig indicate its 
approximate size in bps. The congenic strains are S.LEW- (D8ChmI4-D8RatI6) 
(abbreviated as C8S.Ll) and S.LEW- (D8Rat56-D8Rat51) (C8S.L2), respectively. The 
white bar symbolizes the parental strain, S. 
Figure 19 - Map ofCongenic Strains Constructed 
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Table 7 shows, the new markers constructed in this study to aid in mapping the 
congenic strains. D8 indicates chromosome 8, and Chm, is an abbreviation for the 'Centre 
Hospitalier de l'Université de Montréal' research center where the study was conducted. 
The location of the markers within the supercontigs is indicated, as weIl as the primers and 
size of the PCR product. The tempe rature at which the PCR product is formed is indicated. 
Only the markers that had products and the resulting polymorphisms, if there are any when 
comparing S and LEW, are shown on Table 6. 
79 
Primers Sequences Product Temp. 
Polymorphism 
Rat Marker Supercontig among rat (5' -+ 3') Size (bp) (OC) 
strains 
D8Chm2 NW_047799 
agccatctcctcagcctgta 
512 60 S>LEW 
caacagaaaagcaagcaagc 
D8Chm3 NW_047799 
aggggctgtaccacctttct 
191 60 S=LEW 
gcatgcaatgcctctctctc 
D8Chm6 NW_047800 
gagcagtggagggtagcttg 
369 55 S=LEW 
gctgagggcattgagaagtc 
D8Chm11 NW_047799 
catcctgggctcacaaactt 
457 60 S>LEW 
aggtggggcagccatagtta 
D8Chm12 NW_047799 
aggctacatgggacactgtt 
591 60 S<LEW 
tccaggctccacagtttttc 
D8Chm14 NW_047799 
catctgcatctgcatatctgg 
249 60 S<LEW 
aggaaactgtgggttggaaa 
D8Chm15 NW_047799 
acctctgcccgaacttcttt 
246 60 S=LEW 
ggggaaaggtgtcctgcta 
D8Chm16 NW_047799 
ctgtgctcacaggaggatga 
490 60 S>LEW 
gctgtcctctgaccaacaca 
acgtgtcaccgtgtgtctgt 
D8Chm17 NW_047799 gccttctcagtaccataacctca 375 50,55,60 S=LEW 
ggcagtgcctgagaagaaag 
D8Chm18 NW_047799 cggatgaacttgttgatttctc 458 50,55,60 S=LEW 
accaaatgttttcccccagt 
D8Chm19 NW_047799 tcctgagccttcttccagtt 283 50,55,60 S>LEW 
aggggcgtctgtatgttcac 
D8Chm20 NW_047799 tcacacactggccttcatgt 219 50,55,60 S=LEW 
atcacaggggaaaacagtgg 
D8Chm21 NW_047799 cagaaggctgggaatgtagc 500 50,55,60 S=LEW 
acatgagggaggctgaactg 
D6Chm22 NW_047799 ctactccctccaccctgaca 848 50,55,60 S=LEW 
gaggccttctctgggagagt 
D8Chm23 NW_047798 ctccttcatcaagaatcactgc 241 50,55,60 S=LEW 
tcctcattgaatgctgttgg 
D8Chm24 NW_047798 accgggaaagggaataacac 211 50,55,60 S=LEW 
Table 7 -New microsatellite markers constructed for rat chromosome 8 
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4.2 Telemetry Data 
For aIl four strains, two parental and two congenic strains, the BP components were 
measured, including MAP, DAP, and SAP. One BP reading was taken every 2 minutes 
throughout the period of measurement. Each point on the graphs in Figures 20 and 21 
represents a 6-hour average ofthese readings in order to show diurnal variations. For all the 
strains, BP was measured at two different times of the year using separate litters raised at 
different times, in order to exclude seasonal variations in the measurements. BP for aIl four 
strains was measured simultaneously each time. Figure 20 compares the BP readings of the 
two parental strains. The readings of the LEW and the S rats are indicated in blue and red 
respectively. The BP of the LEW rats had averaged around 96 ± 4 mmHg while the average 
readings of the S rats were higher, around 172 ± 4 mmHg. Results ofDAP and SAP are not 
shown because they are similar to those ofMAP. 
Figure 20 - BP readings comparing the two parental strains, Sand LEW 
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Figure 21 compares in MAP, DAP, and SAP between the C8S.Ll and C8S.L2 
congenic strains and the S strain. Each time-point on the graph represents an average of 6-h 
readings. Each point on the 6-h graph is an average of readings taken at every 2-minute 
interval. Error bars represent the standard error ofmeasurement. The number ofrats is 
given as n. The congenic strains are S.LEW- (D8Chm14-D8Rat16) (abbreviated as 
C8S.LI) and S.LEW- (D8Rat56-D8Rat51) (C8S.L2), respectively. The pattern ofBP in 
each strain was the same when comparing DAP, SAP and MAP. The MAP for C8S.Ll was 
138 ± 5 mmHg while the MAP for C8S.L2 was 197 ± 5 mmHg, greater than that of the S 
rats. We will discuss this observation later. 
Since BPs of strains C8S.LI, C8S.L2, LEW, and S were not different at the separate 
periods of measurement, the BP data was pooled from reproducible measurements for each 
strain. AIl the strains C8S.Ll, C8S.L2, and S had higher BPs than LEW. The region that 
contains the QTL can be localized to the segment that showed significant changes in BPs. 
MAPs, DAPs and SAPs ofC8S.LI were lower (p<O.OOl) than those of the S strain. In 
contrast MAP, DAP and SAP ofC8S.L2 were higher (p<O.OOl) than those of the S strain. 
Figure 22 summarizes the results obtained. 
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Figure 21 - Comparisons of MAP, DAP and SAP of S rats with those of the congenies. 
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Figure 22 - Summary including Statistical Analysis 
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Chapter 5 
Discussion 
5.1 The Presence of Two QTLs with Opposing Effects 
As described in Chapter 4, we bred two congenic strains of rats from nonnotensive 
LEW rats and hypertensive Dahl salt-sensitive S rats. In both of these, alleles from the 
LEW rats were substituted into the S background (since the LEW background is non-
permissive (for further discussion refer to section 5.4), substitution into the LEW 
background would be pointless(17». We called the congenic strains C8S.LI and C8S.L2. A 
BP QTL was mapped to chromosome 8 for each strain. For the C8S.LI strain the QTL is 
located between genetic markers D8Chml2 and D8Chm15, including ambiguous regions at 
both ends of the segment, while for the C8S.L2 strain it is located between D8Rat55 and 
D8Rat51, again including ambiguous regions at the ends (see Figures 20 and 22). The two 
QTLs are separated by 196 cR (centiRays). 
The discovery that there are at least two distinct BP QTLs located near each other 
on chromosome 8 of the S rat is the first main result ofthis study. 
The second result is that the two QTLs have opposite effects on BP. The C8S.LI rat 
had lower BP than the S rat, while the C8S.L2 rat, surprisingly, had higher BP than the S 
rat (see Figure 22). Hence we have designated the two QTLs as the negative BP C8QTL 
and the positive BP C8QTL, respectively. In the latter region, the fact that the LEW aIle les 
increased BP implies that the homologous Salleles would normally lower BP. In previous 
studies on chromosome 8, only a BP lowering effect has been reported. It was only when 
the two regions were separated by congenies that the opposing effects were observed. 
In a previous linkage study (144),no QTL was detected in the region where we have 
found the positive BP C8QTL, but only a weak linkage for the negative BP C8QTL. It is 
only when congenic strains were developed to cover different sub-sections that two QTLs 
with opposite effects were discovered. 
It is interesting that the C8S.L2 strain, created through selection, exhibited 
hypertension more severe than that of the S strain. This hyper-hypertensive strain had BP 
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raising alleles originating from the normotensive LEW strain. This result is surprising, 
because though many congenic strains have been reported by physical mapping ofBP 
QTLs in S rats, most of the BP raising alleles have been associated with the hypertensive S 
rats, whereas the contrasting normotensive strains generally carried BP lowering alleles. 
5.1.1 Epistasis 
Epistasis is the effect of one gene or locus masking or modifying the effect of another. It 
is the relationship between two genes whose products act in the same biochemical pathway 
and in which the functional effect of one gene is masked by another. The masked gene is 
called a hypostatic gene and operates later on the pathway than the masking gene, which is 
called an epistatic gene. A hypostatic gene is unable to produce its usual effect wh en 
coupled with another gene that is epistatic toward it. So, for example, recessive alleles at 
one locus may override expression of alleles at another locus. In this case, the alleles at the 
first locus are said to be epistatic to the masked, hypostatic alleles at the second locus. 
When an allele or alleles at one locus require the presence of specific alleles at another 
locus, these pairs are said to complement each other; this is another example of epistasis. 
An additive relationship between two QTLs occurs when the SUffi of the BP effects of each 
QTL taken individually is equal to the BP effect of a congenic strain containing both QTLs. 
In contrast, an epistatic relationship occurs when the individual QTL BP effects are not 
equal to that of a congenic strain containing both QTLs resulting in synergism. 
The BP of the C8S.L2 strain was higher than that of the S strain, due to the presence 
of alleles from the normotensive LEW strain. The result implies that alleles at other 
locations in the LEW strain interact with the positive BP C8QTL to prevent such a rise in 
BP, and that the se alleles are not present in the S strain. It is possible that, in creating the 
C8S.L.2 strain, the genetic background of S rats was incapable ofbuffering the BP change 
that resulted. 
Epistasis has been shown to exist in previous BP congenic studies, involving 
chromosome 3 (134) and chromosome 2(18). Since the positive BP C8QTL was not 
detected in the earlier linkage study of the F2 population, it is possible that the effect of the 
positive BP C8QTL might have been masked by other BP QTLs and only emerged after the 
latter were removed. Such a masking effect would indicate epistasis. Again, when moving 
the BP-raising LEW alleles into the S genetic background, the BP-raising alleles may have 
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found a complement to act in synergism with, in the S genetic background, resulting in the 
hyper-hypertensive phenotype. 
In contrast to the positive BP C8QTL, LEW rats carry BP-lowering alleles at the 
negative BP C8QTL. In a previous linkage study (59), on which the present study is based, 
only a weak BP lowering effect was observed. In that study, the BP lowering effect reached 
a suggestive statisticallevel of significance. This could indicate that in the previous study 
the alleles located in the regions delimited by the two BP Q1Ls interacted with each other, 
resulting in an overall mild phenotype that lowered the BP in the F2 generation. 
Since the earlier linkage study was only considering the F2 generation, which was 
heterozygous for the region in question, it is also possible that the effects on BP caused by 
the L alleles could have been masked. This masking could take the form of a biochemical 
product that is produced by the Salleles, but not by the LEW alleles. When the genotype is 
heterozygous SL, the presumed biochemical product that raises BP is produced by S, would 
compensate for the lack of the biochemical product not being produced by L alleles to a 
certain degree. Whereas, when the region is homozygous LL, there is no compensation, 
hence BP is reduced. Perhaps the effects of the negative BP C8QTL dominate those of the 
positive C8 BPQTL. The present work illustrates the value of dissecting suspected Q1L 
fragments using congenic strains. 
5.1.2 Ove ra Il Phenotype versus Individual QTLs 
It seems surprising, as we have noted, that the normotensive LEW rats appear to 
carry BP-elevating alleles. When the QTL region containing LEW alleles was compared 
with the Salleles in the same region, it was found that the LEW rat raised BP higher than 
the hypertensive S rat. 
This is not an extraordinary finding since we have seen that BP raising QTLs and 
BP lowering QTLs can be found within the same strain. Thus it appears that both the net 
normotensive LEW phenotype and the net hypertensive S phenotype may result from 
interactions between BP raising and BP lowering QTLs. Both LEW and S strains are 
inbred, and during their selective breeding various aIl el es could have become fixed 
randomly, a BP raising allele for that Q1L could have become fixed in the LEW rat, while 
at the homologous region in the S rat, a BP lowering allele for that QTL could have become 
fixed. It is only when the regions are isolated, as in a congenic strain that the effect of the 
individual QTL is observed. 
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Thus the hypertensive nature of the S strain could be explained by the fact that it has 
many more BP raising alleles compared to BP lowering alleles, while conversely the 
normotensive LEW strain could have a numerical advantage in terms of BP-lowering 
alleles. In both parental inbred strains only the overall phenotype is seen. 
Similarly, it is possible that more than one BP QTL is located within each of the 
QTL segments defined by C8S.L1 and C8S.L2 congenic strains. Further subdivision of the 
concemed regions might bring to light the existence of smaller QTLs within the larger 
regions, as weIl as possible epistatic effects. 
5.2 Physiological Analysis -Measuring BP 
Genetic studies can present evidence of genes implicated in hypertension, but they 
cannot show the mechanism by which hypertension is physically caused. Therefore, genetic 
studies cannot replace physiological studies; instead, each must complement the other. The 
measurement of arterial pressure, whether it be systolic, diastolic, or mean pressure, permits 
the direct association between a physiological, quantitative aspect of hypertension and a 
genetically delimited region on a chromosome. The three principal methods of measuring 
arterial pressure in rats are by tail cuff, by telemetry and by indwelling catheter(31). Each 
process has its own advantages and disadvantages (summarized in Table 8(31)). 
5.2.1 Tail euff 
In the tail cuff method of BP measurement, the rats are preheated in a chamber at 
35°C for 10 minutes, then placed in plastic restrainers. A cuffwith a pneumatic pulse 
sens or is attached to the tail and BP is then measured. The tail cuff method is best method 
of initial general targeting ofBP differences in rats. It is a broadly applicable method to 
determine whether susceptible chromosomes contain a QTL for BP. However, the 
measurement is indirect, and the requirement for animal heating and restraint may cause 
stress-induced changes in BP. It is also unreliable for measuring DAP and MAP 
(53,82,101,202). 
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5.2.2 Telemetry 
In telemetry, a radiotelemetric monitoring system continuously measures 
cardiovascular parameters in freely moving rats. When direct observation is impossible, 
telemetry allows animaIs to be monitored with minimum restraint and allows for 
reproduction of the transmitted data. It allows for monitoring physiological variables su ch 
as BP by pro vi ding a wireless link between the subject and the data collection equipment. 
The transmitting unit (probe) is surgically implanted in the abdomen, allowing for the 
subjects to be freely moving and conscious. If animaIs are tethered, they are prone to exit-
site infections. Once the telemetry probe is implanted, data can be monitored 24 hours per 
day without human intervention or contact. Telemetry, being a more direct method than the 
tail cuff, is best for monitoring small changes in BP, such as diurnal and seasonal 
variations, as well as additive effects. It allows for a wide spectrum of environmental, 
physiological and behavioural data to be monitored. 
5.2.3 Indwelling Catheter 
In order to implant a rat with an indwelling catheter, it is first anaesthetized with 
drugs that cause hypotension and reduce HR. It then undergoes cannulation of the right 
carotid artery. The catheter is connected to a pressure transducer. BP measurements using 
the indwelling catheter allow for direct and accurate for measurement of SAP, DAP and 
MAP. Like telemetry, the catheter permits continuous, long-term monitoring. It is more 
economical than telemetry. Similarly to telemetry, it is invasive and may result in stress due 
to the necessary surgery to insert the catheter. There is also a high risk of infection resulting 
from the inserted catheter. Although BP can easily be measured in anesthetized rats in this 
way, repeated measurements taken over long periods oftime in awake rats are much more 
difficult to make using this method. 
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Table 8 -Advantages and disadvantages in the three principle methods for measuring 
BP in the rats 
Method Advantages Disadvantages 
Tail Cuff - Non invasive -Low accuracy 
- Inexpensive -Stress imposed by immobilization 
- Rapid for measuring SAP -Indirect measurement ofBP 
-Unreliable measure of DAP and MAP 
- Vasoconstriction 
- Cannot monitor for long-term 
- Induce warmth in the experimental animal 
- Changes in BP of less than 10 mmHg hard 
to detect 
Telemetry - Accurate for measuring -Expensive in terms of equipment, 
SAP, DAP and MAP monitoring and maintenance of equipment 
- Direct measurement of BP -Invasive 
- Allows for long-term -stress due to surgery 
chronological monitoring 
Indwelling Catheter - Accurate for measuring 
SAP, DAP and MAP 
-Invasive 
-
Direct measurement of BP 
- Permits continuous, long- - Infections could arise 
term monitoring 
- Economical compared to 
telemetry 
Table 8 is based on Deng 1998 (31). 
5.3 Gene-Environment Interaction 
Previous linkage studies (59)seem to have overlooked the strong positive BP raising 
effect we have observed in our congenic study. One possible source ofthis difference is the 
phenotyping protocol used. In the linkage study, phenotyping was done by tail cuff, while 
in the present work, it was done by telemetry since it is a less intrusive method of 
monitoring BP. 
Another consideration is that in the linkage studies (59), the rats were fed an 8% 
NaCI diet, whereas in the present investigation, the rats were fed a 2% NaCI diet. The 
reason for using these differing diet protocols is as follows. It has been shown that LEW 
rats are extremely salt resistant, even on an 8% NaCI diet, while this di et is toxic to S rats 
(59). The rats in the F2 population of the linkage study contained more than 25% of the 
LEW genome, so that the F2 cohorts could survive on an 8% diet until the end ofBP 
measurements (59). The S rat, which was the genetic background for the congenic strains, 
contained none of the LEW genome. A detailed survival study ofS rats by Cicila et al. 
(22,24), showed that on a 2% NaCI diet for 42 days, S males were still alive, whereas on a 
4% NaCI diet the mean survival time was oruy about 39.8 days. It was reasoned that S rats 
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would not survive on an 8% NaCI diet for the duration of our experiment, that is, 50-58 
days starting from the onset of the salt-containing diet. For this reason, the S rats and 
congenic rats were fed a 2% salt diet uniformly to make sure that they would survive long 
enough to have their BPs measured (23,31,32,36,40,44,127,134) .The choice ofthe 2% 
NaCl diet in the present study is a compromise between survival of the animaIs and a 
sufficient life span to measure BP adequately. 
The presence of a positive BP C8QTL in our LEW normotensive strain indicates 
that LEW does carry BP-raising alleles, despite its generally low BP. When placed into an 
appropriate genetic background, these BP raising alleles seem to be sufficient to increase 
the BP of the S strain. 
Interestingly, in contrast to S rats, which normally live for 20-30 days under our 
experimental conditions, most of the C8S.L2 rats died by day 8 ofmeasurements, probably 
due to fatally high BP. This result implies that in the genetic background of S rats there is 
an upper limit for BP in response to a high salt diet and C8S.L2 is close to reaching it. We 
now discuss genetic background effects. 
5.4 The Genetic Background and its Effects 
The genetic background effect is the influence of the genome as a whole on the 
materialization of the phenotype. The manner in which the genes located in the background 
interact with the genes in the targeted chromosomal region, together with the net effect of 
those genes, determines what the observable phenotype will be. 
A strain is said to have a permissive genetic background when the net effect of the 
genes outside the targeted region does not overshadow the manifestation of the phenotype. 
If the effect of the genetic background overshadows the effect of the alleles located in the 
targeted region, the genetic background is non-permissive. A strain with a permissive 
genetic background will have variation in BP wh en compared to the parental strains. If the 
background is non-permissive, then no observable change in BP should be seen when 
compared to the parental strain. 
One way to verify the effect of the genetic background of a strain is to conduct a 
test ofreciprocity, which permits the isolation of the effect ofcontrasting alleles ofa QTL 
on phenotype. In a test ofreciprocity for strains A and B, say, one congenic strain is 
produced in which a region of A is transferred to the B background, while a second 
congenic strain is produced transferring the homologous region ofB to the A background. 
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If a difference in phenotype is detected in the second congenic strain and not in the first, it 
is said that A is a pennissive genetic background while B is non-pennissive. 
ln this study, nonnotensive LEW alleles were introgressed ioto the S genetic 
background, which is seen to be pennissive because the congenic strains show differences 
in BP compared to the LEW and S strains. Ongoing studies have shown, using congenics 
targeting other chromosomes together with a reciprocity test, that the LEW genetic 
background is non-pennissive(17). Furthennore, in those studies, it is reasoned that because 
the BP of the S strain can be increased or decreased in congenic strains, the physiological 
capacity to buffer or modulate BP changes in the S rat has been weakened (17). For this 
reason, we did not develop any congenic strains using the LEW background. 
Dahl salt resistant R rats, which are also nonnotensive, are the usual candidates for 
linkage and congenic BP analysis in conjunction with Dahl salt sensitive S rats. Both LEW 
rats and R rats have non-pennissive backgrounds. But this is only true for the effects of 
particular chromosome sections from particular strains on a specific phenotype(148). 
Moreover, LEW rats are slightly more resistant to salt induced hypertension than R rats 
(59),even though R rats have been selectively bred for such resistance while LEW rats have 
not. However, LEW rats show approximately 45% of microsatellite markers polymorphic 
with S, but between Rand S only 18% are polymorphic (83). The higher polymorphism 
rate between Sand LEW is an advantage in a genome scan. This advantage is the reason we 
have used LEW rats rather than R rats as the nonnotensive control strain. 
It is important to consider other potential confounding influences due to genetic 
background effects. These inc1ude epistasis, other influences of alleles outside the target 
regions, possible polygenetic effects, and effects due to difficulties in accurate mapping of 
the target region. 
Ideally, if the genetic background has no influence on BP, the targeted QTL would 
be the cause of aU variations in the congenic strain. However, there is a possibility that 
epistasis deriving from the genetic background might introduce masking or synergistic 
confounds into the results deriving from the congenic strains. 
Furthennore, though our study tentatively interprets the variation of BP as a 
monogenic effect, it is possible that BP variation correlates to a group of several LEW 
alleles rather than to one specific allele. 
Finally, congenic strains may pro duce misleading results due to the size of the 
chromosomal segment that is introgressed together with the gene of interest. (In our case, 
92 
for example, after 10 backcrosses the fragment from the donor strain is still approximately 
20 cM in length and contains approximately 1.3 % of the genome.) If the trait analyzed is 
controlled by a large number of genes, as is the case, for example, for neural or behavioral 
processes, it can be difficult to distinguish between the effect of the gene of interest and the 
effects of genes located in the flanking chromosomal segment. One way to minimize this 
effect is to derive a series of partially overlapping congenic strains (Figure 23). If these 
strains are derived independently, the residual segments from the donor strain are different 
and the genes that are not tightly linked to the mutation or allele are not present in all 
strains. By comparing the phenotypes of the different congenic strains, it is possible to 
distinguish between the effects of the mutation or allele itself and the effects of the flanking 
genes. 
Despite these limitations, congenic strains are invaluable genetic tools for several 
reasons. First, a given phenotype can be studied in different genetic backgrounds. Second, 
congenic strains allow confirmation of results identified by linkage analysis. They are also 
helpful for study of the pathophysiologic features associated with a given genomic region. 
Because the congenic strain differs from the recipient strain by a small chromosomal 
segment selected during the backcross generations, any phenotypic differences observed 
between these two strains can be attributed to this segment, under limitations described 
above. Congenic strains are powerful tools to refine the location of a QTL, by generation of 
"subcongenic" strains carrying smaller, partially overlapping chromosomal segments 
(Figure 23). This strategy can narrowthe candidate interval to <1 cM, a resolution that 
cannot be approached by linkage studies. An additional advantage of congenic strains is 
their usefulness for the detection of loci with minor phenotypic effects. After a major 
modifier locus has been mapped and introgressed in a congenic strain, a two-generation 
cross between this congenic strain and the donor strain can be generated. Because the major 
modifier locus is not polymorphic in the cross, its major effect no longer hides the more 
mode st effects of other loci. Finally, congenic strains are ideal fortesting epistatic 
interactions between modifier loci, because homogenous populations can be produced for 
each genotypic combination and their phenotypes can be compared. Although a single 
congenic strain might not always be sufficient to yield clear conclusions, multiple congenic 
strains are ideal tools for the analysis of interactions between the genetic background and 
genes responsible for Mendelian traits. 
The fact that background genes can influence the phenotype induced by a single 
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gene mutation or allele should not be surprising. Probably few genes work in such a way 
that other genes cannot modulate the effects of altering them. Metabolic pathways, 
developmental processes, and the variation in levels of gene expression all result from 
protein-protein and protein-DNA interactions. The modification of any component of the se 
networks may influence the other components. 
In other words, a phenotype is context dependent. A mutation induces a phenotype 
in a particular genetic context, dependent on factors such as environment, experimental 
conditions, and genetic background. Since genetic mapping is a tool for associating 
physiological traits to the genome, it is context dependent as well, since genetic background 
effects have a significant impact on the traits that can be mapped. Before making general 
interpretations of physiological measurements, it is important to remember that the genetic 
background can significantly affect not only baseline measurements but also the response 
to, say, gender-related or environmental stimuli (103). 
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Deducing from the hypothetical situations above: ln the first situation ifthere is one QTL, the phenotypic 
effect and location of the QTL can be deduced from the subcongenic lines. In the second situation: If the 
control strain had a BP of 180, QTL A increases BP when isolated, while QTL B not only decreases BP, 
but masks the effect of QTL A. Somehow QTL A and B are interacting to decrease BP more than wh en 
QTL Bis acting by itself. 
Figure 23 - Deducing the Effect QTLs Using Congenies 
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5.5 Other Limitations and Potential Sources of Error 
Our study is subject to certain limitations and potential sources of error, due to 
decisions we had to make in order to focus the results. These include experimental 
measurement conditions, cross-specificity, age and gender-specific selection. 
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First of ail, the conditions under which BP is measured during breeding are 
important. Many environmental factors can affect BP, e.g., the stress ofbeing restrained, or 
dietary factors such as potassium intake. Therefore it is crucial to control the experimental 
environment and to treat the animais uniformly. 
Secondly, linkage analysis and analysis using congenic strains are both limited in 
that they use a segregated population resulting from the backcrossing of two unique inbred 
strains. Therefore the results could be cross specific, due to the effect of the genetic 
background of the recipient strains on the expression alleles of QTLs of the donor strain. 
One must therefore mate individuals using a uniform selection process, in order to avoid 
fixing different alleles and confounding the genetic background. This is another argument 
for uniform treatment of the animais. 
In fact, the detection of a QTL depends strongly on the identity of the two strains 
bred together to obtain the segregated population. The present study is limited to the 
comparison of the Dahl S strain and the Lewis strain. To bypass this limitation, one 
alternative is to study other contrasting strains, e.g., the SHR strain and the Milan 
normotensive strain. 
Another limiting factor is the age of the animaIs. Most studies are done on adult 
animais, since BP increases with age and during development (145) . It has been pointed 
out that certain genetic effects on BP may be due to components that can only be observed 
during birth and development (163,187). At various stages in the lifespan of the rat, 
different genes come into play, ail ofwhich could have various effects on BP. Moreover, 
monitoring BP throughout a rat's lifespan is very costly. For aU these reasons, the aspect of 
BP variation in development was ignored. Our analysis is limited to animaIs aged from 8 to 
12 weeks. 
Finally, we have studied only male rats. In terms of hypertension, specifically BP, 
there are differences between the sexes. Male rats develop hypertension faster than 
females( 4). In a female rat in estrus, BP varies cyclicaUy according to hormonal influences 
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(145). The variation in BP due to hormonal changes might result in background 
interference that would have complicated conclusions drawn from the results. Ifthis study 
had been conducted on both sexes, it would have complicated the experimental design. It 
should be understood that conclusions drawn from this study should be restricted to males. 
5.6 The QTL Regions 
5.6.1 Reproducibility of the Negative BP QTL 
Comparing the results of the present study to those of studies conducted in other 
laboratories (59,94,98,169,190), we see that other investigators have found BP C8QTLs in 
regions near those where ours are located (Figure 24). It is possible that the QTLs we have 
found could be responsible, in part, for the hypertension seen by other researchers. 
The data published by Garrett et al. (59) was the base for the development of the 
current congenic rats in this study. In Garrett's study, the region found is smaller and only a 
weakly suggestive linkage LOD was reached where BP was lowered mildly. This finding 
might indicate the presence of other QTLs involved in the phenotype of the negative C8 BP 
QTL. 
Even though Kren et al.(98) and Khan et al. (94) both used congenic strains in their 
studies, only a negative BP QTL was found. In Kren's study this QTL exerted major 
effects on BP and cardiac mass in the SHR. Khan' s study found reduced BP in a C8 region 
that con tains a gene cluster for three nicotinic receptor subunits expressed in the nervous 
system. In the study, this cluster was implicated in nociceptive and BP 
hyperresponsiveness. Finally, our negative BP C8QTL falls within the same region as the 
BP lowering QTL found by Ueno et al. (190) in pharmacogenetic study in which the SNS 
was blocked. 
In a linkage study conducted by Takami et al. (184) there was a hypotensive effect 
on C8 at the peroxisomal 3-keto acyl CoA locus in the F2 progeny obtained by crossing of 
Iwai salt-sensitive rats and Wistar-Kyoto rats. In a genome scan conducted by Schork et al. 
(169) using F2 progeny obtained from a cross between Brown-Norway and SHR rats, a BP 
increase was found when salt-Ioaded SBP was measured. Both ofthese regions coincide 
with regions we isolated in both the negative and the positive BP C8 QTL. 
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Figure 24 - Localizations of two quantitative trait loci (QTLs) and comparative 
mapping 
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Figure 24 is a comparative map ofhomologous regions found in the mouse and human. The 
rat linkage map shown is the same as in Figures 19 and 22. The positions of the QTLs are 
those defined by the congenic strains shown in Figure 19. Genes indicated on Figure 24 in 
the homologous regions on rat chromosome 8, mouse chromosome 9 and human 
chromosomes Il, 15 and 19 are based on information found in the NeBI database located 
at http://www.ncbi.nlm.nih.gov/mapview/. The figure lists most ofknown genes for the 
positive BP QTL region. Among over 80 genes found in the negative BP QTL region, only 
selected genes are listed based on their potential roles in BP regulation. QTL localizations 
from the present work and others are shown to the right of the linkage map for comparison. 
Genes are as follows: APOA5, apolipoprotein A-V; AQP9, aquaporin 9; B3GATl, beta-l, 3-
glucuronyltransferase 1 (glucuronosyltransferase P); CHRNA3, cholinergie receptor, nicotinic, 
alpha polypeptide 3; CHRNA5, cholinergie receptor, nicotinic, alpha polypeptide 5; CHRNB4, 
cholinergie receptor, nicotinic, beta polypeptide 4; CNN1, calponin 1, basic, smooth muscle; 
CRYAB, crystallin, alphaB; CSNK1Gl, case in kinase 1, gamma 1; DNM2, dynamine 2; DRD2, 
dopamine receptor D2; ELA VL3, ELA V (embryonic lethal, ab normal vision, Drosophila)-like 3 
(Hu antigen C); FAn, fat3 protein; FDX1, ferredoxin 1; FUT4, fucosyltransferase 4 (alpha (1,3) 
fucosyltransferase, myeloidspecific); FXYD2, FXYD domain containing ion transport regulator 2; 
GPR72, G protein-coupled receptor 72; Gpr83, G protein-coupled receptor 83 (glucocorticoid-
induced receptor); GRIK4, glutamate receptor, ionotropic, kainate 4; HCN4, hyperpolarization 
activated cyclic nucleotide-gated potassium channel 4; HNT, neurotrimin; HSPB2, heat shock 27 
kDa prote in 2; HTR3A, 5-hydroxytryptamine (serotonin) receptor 3A; HTR3B, 5-
hydroxytryptamine (serotonin) receptor 3B; IL18, interleukin 18 (interferon-gamma~inducing 
factor); ILF3, interleukin enhancer binding factor 3, 90 kDa; lREB2, iron-responsive element 
binding prote in 2; Is12, insulin related protein 2; ISL2, ISL2 transcription factor, 
LlMlhomeodomain, (islet-2); KCNJ5, ATP-sensitive, inwardly rectifyingpotassium channel of the 
subfamily J; MCAM, l-gicerin, melanoma cell adhesion molecule; MREllA, MREll meiotic 
recombination Il homo log A (S. cerevisiae); MTNR1B, melatonin receptor lB; MYOlE, myosin 
lE; MY09A, myosin lXA; NCAM1, neural cell adhesion molecule 1; NEOl, neogenin; OPCML, 
opioid binding proteinl cell adhesion molecule-like; PAF AHI B2, platelet-activating factor 
acetylhydrolase, isoform lb, beta subunit 30 kDa; PPIS, peptidylprolyl isomerase B (cyclophilin B); 
RAB3D, RAB3D, member RAS oncogene family, RCN2, reticulocalbin 2, EF-hand calcium 
binding domain; RNU16845, neurotrimin; SMARCA4, SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, member 4; TAGLN, Transgelin (smooth muscle 22 
protein); TGT, tRNA-guanine transglycosylase; TPM1, tropomyosin l, alpha. 
99 
5.6.2 Comparative Mapping and Potential Candidate Genes 
The region containing the negative BP C8QTL in the rat shares regions of 
conserved synteny with a segment ofmouse chromosome 9, and segments ofhuman 
chromosomes Il and 15. The region harboring the positive BP QTL is homologous to a 
fragment ofmouse chromosome 9, and to sections ofhuman chromosomes Il and 19 
(http://www.ncbi.nlm.nih.gov/mapview/). Since the general purpose of aIl animal 
hypertension studies is to gain more information in order to understand how human BP loci 
are implicated in BP control, it is important to do comparative mapping to find homologous 
genes in both mouse and human. Reproducible rat and mouse QTLs present good 
candidates for comparative mapping in human hypertension. Candidate genes in BP 
regulation include genes coding for or involved in the foIlowing: adrenergic receptors, ion 
channels or transPorters, proteins regu1ation or involved in catecholamine biosynthesis, 
metabolism or transport, nicotinic cholinergic responses, the NO system including nitric 
oxide synthases, various peptides and receptors, prostacyclin; RAAS system, serotonergic 
responses, signal transduction, various oxygenases, proteases and nuclear hormone 
receptors. 
We now de scribe selected genes that faIl within the regions delimited by the BP 
QTLs we have located, which have been described in other studies as candidates for BP 
regulation. 
5.6.2.1 Ion Channels 
Ion channels are involved in determining the movement of ions into and out of ceIls, 
and so are crucial for the electrical activity of nerves, muscles and sensory organs and are 
central to homeostasis. They play an important role in regulating BP. It is believed that 
defects in ion channel proteins may underlie sorne forms ofhereditary hypertension, 
thereby making ion channels attractive targets for study (8). 
5.6.2.1.1 Potassium Channel (Kcnj5) 
The gene Kcnj5 faIls in the positive BP QTL region. Kcnj5 encodes for an ATP-
sensitive, inwardly rectifyingpotassium channel of the subfamily J. Potassium channels are 
present in most mammalian ceIls, where they participate in a wide range of physiologic 
responses. The protein encoded by this gene is an integral membrane protein. The encoded 
protein, which has a tendency to allow potassium to flow into rather than out a cell, is 
controlled by G-proteins. It may associate with two other G-protein-activated potassium 
channels to form a heteromultimeric pore-forming complex (96). Kcnj5 is expressed in 
heart tissue. Knockouts ofthis gene have suggested that Kcnj5 is involved in vagal 
regulation ofheart rate as well as spatial memory. 
5.6.2.1.2 FXYD2 Protein-Sodium Potassium Pump Activity Modifier 
100 
There is a gene coding for the FXYD2 protein in the negative BP QTL region. This 
protein modulates the activity of the sodium-potassium pump. The sodium-potassium 
ATPase or NaIK pump belongs to the protein family ofP-type ATPases that are 
characterized by the formation of a phosphorylated intermediate during the catalytic cycle. 
By using the energy ofhydrolysis of ATP, Na-K-ATPase located in the plasma membrane, 
transports three Na+ ions out of the cell in exchange for moving two K+ ions into the cell. 
Na-K-ATPase is an oligomeric protein.lts catalytic subunit, having ten 
transmembrane segments, transports the cations, hydrolyzes ATP, and is the 
pharmacological receptor for cardiac glycosides. Na-K-ATPase is the transport system 
responsible for the maintenance of the Na+ and K+ gradients across the plasma membrane. 
These gradients are essential to maintain cell volume and membrane potential, and the Na + 
gradients provide the energy for the activity of secondary Na + dependent transport systems 
that supply the cell with nutrients and regulate intracellular pH and Ca2+ concentrations. 
Na-K-ATPase is present in aIl cells to ensure basic cellular homeostasis, but it also 
contributes to specialized tissue functions. In the kidney, Na-K-ATPase is exclusively 
located in the basolateral membrane of epithelial cells, and thus becomes the driving force 
for Na+ reabsorption essential to maintain extracellular volume and BP. Numerous 
mechanisms are involved in the regulation of the Na-K-ATPase to adapt its activity or 
expression to accommodate changing physiological demands. Because intracellular Na + is 
the limiting factor for Na-KATPase activity, any change in the intracellular Na+ 
concentration affects its transport rate. Moreover, peptide hormones or neurotransmitters 
may provoke phosphorylation of Na-KATPase by protein kinases, which modulate its cell 
surface expression. Finally, steroid hormones such as aldosterone affect gene transcription, 
leading to an increased number ofNa-K-ATPase pump units. 
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In addition to regulatory effects mediated by hormones and neurotransmitters, there 
is a novel regulatory mechanism that involves interaction ofNa-K-ATPase with small-
membrane proteins of the FXYD family. In contrast to hormonal regulation, interaction of 
FXYD proteins does not produce a change in Na-K-ATPase expression but rather modifies 
the transport properties of the Na-K-ATPase in a tissue- and isoform-specific way. The 
gene family of FXYD proteins is based on the invariant amine acids in a signature 
sequence containing the FXYD motif tog~ther with two conserved glycine and a serine 
residues. In mammals, this family contains seven members. FXYD proteins contain 61 to 
95 amino acids. 
There is a FXYD2 gene in the region delimited by the negative BP QTL. FXYD2 is 
the y-subunit ofNa-K-ATPase. It is a type l membrane prote in with a single membrane 
span and the COOH terminus exposed to the cytosol, having no signal peptide. The 
transmembrane domains of FXYD2 adopt a a-helical conformation. FXYD2 is associated 
with renal Na-K-ATPase and it modulates Na-K-ATPase activity, to produce a functional 
effect on its transport properties. FXYD2 is predominantly expressed in the kidney, with 
segment specific distribution of FXYD2a and FXYD2b . FXYD2a and FXYD2b colocalize 
with Na-KA TPase in the basolateral membrane of renal epithelial cells. FXYD2 has been 
shown to increase the apparent K+ affinity ofNa-KATPase at high negative membrane 
potentials in both the presence and absence of extracellular Na+. FXYD2 decreases the 
apparent K+ affinity at less negative membrane potentials but only in the presence of 
extracellular Na+. FXYD2 aiso increases the affinity for ATP. FXYD2 increases the K+ 
antagonism ofintracellular Na+ binding, suggesting an additional effect ofFXYD2 on 
intrinsic binding ofK+ at cytoplasmic sites. Finally, FXYD2 decreases the Na+ activation of 
Na/K pump currents and produces a paraUel decrease in the Na + and K+ activation of Na-
KATPase activity. It is speculated that in the kidney, FXYD2, which decreases the Na+ 
affinity ofNa-K-ATPase, favors the existence oflow-Na+ affinity Na-K-ATPase in the 
kidney, which may in tum be favorable for an efficient reabsorption of Na + in renal 
segments with high cellular Na + load (68). 
5.6.2.2 Cytochrome P450 Enzyme CYPIAI 
CYPIAI is a member of a large class of cytochrome P450 enzymes. Human 
CYPIAI is expressed extrahepatically, and contributes to the detoxification of a variety of 
xenobiotics, such as the conversion of polycyclic aromatic hydrocarbons or aromatic 
amines that are constituents oftobacco smoke. This enzyme transforrns arachidonic acid 
and eicosapentaenoic acid into vasodilator compounds. 
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Induction ofa CYPIAI by various environmental products, including cigarette, 
smoke is regulated by the aromatic hydrocarbon receptor (ARR). A polymorphism of the 
gene CYPIAI (T3801C polymorphism), which is associated with higher CYPIAI 
inducibility and enhanced catalytic activity, has been linked to stroke and triple vessel 
disease, and may, thus, be associated with BP. In addition, genetic deletion of ARR in mice 
can lead to cardiac hypertrophy and elevated arterial BP by five months. Based on the 
known relationship between CYP 1 A 1 T3 80 1 C and t ARR G 1661 A polymorphisms and the 
cigarette-smoking-related risk of cardiovascular disease, it has been speculated that a 
dysregulation ofCYPIAI expression, due to ARR G 1661A polymorphism or CYPIAI 
T3801C polymorphism or both, would lead to significant changes in vascular homeostasis 
and thus BP(57,58,165). 
Men carrying the less frequent CYPIAI allele (TC and CC genotype) tend to have 
higher SBP and DBP than homozygous carriers of the more frequent allele (TT genotype). 
It has been demonstrated that ARR-null mice develop an elevation in arterial BP as early as 
two months of age, indicating that ARR contributes to BP regulation. ARR-null mice also 
develop cardiac hypertrophy associated with increased expression of vascular endothelial 
growth factor. ARR is transcriptionally activated by cigarette smoke condensates. Human 
carriers ofboth rare CYPIAI and ARR alleles exhibited the highest SBP when they quit 
smoking or never smoked. This indicated to the researchers that ARR contributes to the 
regulation of BP via an interaction between the G 1661 A polymorphism and the CYP 1 A 1 
T3801C polymorphism(57,58,165). 
It had been found that smooth muscle cells of ARR knockout mice respond in a 
very divergent way to classic inducers, when compared to cells ofwild-type mice. As many 
as 107 genes have been seen to respond differently to inducers between wildtype and ARR 
cells, including transforming growth factor-beta and insulin-like growth factor-1. TGF-b 
and IGF-I signalling have been reported to contribute to the modulation ofBP. Three other 
different CYPs, namely CYP2C9, CYP3A5 and CYP4All, have been reported as 
candidate genes in hypertension, according to gender and ethnicity. Healthy control 
Chinese women have higher CYP2C9-3 allele frequency than hypertensive women. The 
CYP3A5-1 allele is more common in hypertensive African-American individuals, but this 
allele appears not to contribute to BP in Caucasians. A 10ss of function variant of 
CYF4All (8590C allele) is associated with hypertension in Caucasian individuals(58). 
5.6.2.3 Alpha B Crystallin 
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Alpha B-Crystallin is a small heat-shock protein which is constitutively expressed 
in various tissues, including the lens of the eye (9). It has been suggested that alpha B-
crystallin provides lens transparency, but its function in nonlenticular tissues is unknown. It 
has been reported that alpha B-crystallin is involved in the stabilization and the regulation 
ofparts of the cytoskeleton, such as intennediate filaments and actin. There is a possibility 
that alpha B-crystallin interacts with microtubules, which are a component of the 
cytoskeleton. One of the functions of alpha B-crystallin is to bind microtubules via 
microtubule associated proteins and to give the microtubules resistance to disassembly (56). 
It is also implicated in cardiac stress(80). 
During ischemia, alpha B-crystallin has been shown by immunoelectron 
microscopy to translocate to the N(2)-line area of myofibrillar I-bands of rat 
cardiomyocytes where it resisted extraction with 1 m NaSCN and 2 m urea, as did titin, 
which is also known as connectin (71). Titin is a protein involved in the contraction of 
striated muscle tissues. Titin connects the Z line to the M line in the sarcomere. It limits the 
range of motion of the sarcomere in tension, thus contributing to the passive stiffuess of 
muscle. Variations in the sequence of titin between different types of muscle (e.g. cardiac 
or skeletal) have been correlated with differences in the mechanical properties ofthe 
muscles (76). Binding of alpha B-crystallin to titin during cardiac ischemia could serve to 
stabilize titin against denaturation and might provide an endogenous mechanism to delay 
ischemic damage ofthis important elastic component ofmyofibrils (71). 
5.6.2.4 Neuropeptide Y Family Member- GPR72 
The neuropeptide Y gene family mediates important physiological effects on 
appetite, regulation ofBP, reproduction and anxiety in humans through interaction with 
specific G-protein-coupled receptors including GPR72. According to the GenBank 
Database, GPR72 is related to a glucocorticoid-induced receptor found in the brain which 
may be involved in behavioral sensitization. GPR72 has been identified as the human 
homologue of the mouse orphan receptor GIR, showing 85% amino acid identity. GPR72 is 
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expressed in regions of the hypothalamus, hippocampus and amygdala in both rodents and 
humans (70). GPR72 was previously suggested to be a new NPY receptor, but experiments 
showed that it does not bind NPY -receptor ligands in standard binding assays. 
5.6.2.5 Nieotinie Cholinergie Reeeptors 
The genes of the cholinergic nicotinic receptor cluster, which are implicated in 
Khan et al. (94) as candidate genes in BP control and nociception, faU within the negative 
BP QTL region. In the congenic strains studied by Khan et al. and in the C8S.L 1 strain of 
the current study, BP was lower than that of the S strain despite the differences in the 
parental strains. The neuronal nicotinic acetylcholine receptor subtypes a3, aS, and ~4 are 
members of a ligand-gated ion channel family that affect sodium and potassium transients. 
Cholinergic receptors can be divided into two types, muscarinic and nicotinie, based 
on the pharmacological action ofvarious agonists and antagonists. Muscarinic receptors 
were originally distinguished from nicotinic receptors by the selectivity of the agonists 
muscarine and nicotine respectively. Nicotinic receptors produce pharmacologically and 
physiologically distinct responses from muscarinic receptors, although acetylcholine 
stimulates both types of response. Nicotinic responses are of fast onset, short duration and 
excitatory in nature. The pharmacology of nicotinic receptors has been studied in detail and 
our understanding ofhow ion channel-coupled neurotransmitter receptors work is based 
largely on the study of this class of proteins. 
Nicotinic receptors are found in a variety of tissues, including the autonomie 
nervous system, the neuromuscular junction, and the brain in vertebrates. They are also 
common in the electric organs of various electric eels and rays. The large quantities of 
receptors in these tissues and the use of neurotoxins from snake venom that bind 
specificaUy to the nicotinic receptor have been used in the purification of the receptor 
protein. Agonists su ch as acetylcholine, carbamylcholine and nicotine pro duce the 
physiological responses associated with nicotinic cholinergic activation. Acetylcholine 
produces an influx of sodium through a ligand-gated ion channel. 
The nicotinic receptor consists of five polypeptide subunits. The amino acid 
sequence for the a subunits consists of a glycolipid region with four hydrophobie regions 
that span the membrane. In the neuromuscular junction, d and g subunits also have been 
identified. The g subunit is replaced by an e subunit in the adult muscle. a-Bungarotoxin 
105 
binds to the a and b subunits and probably blocks both the receptor channel and the ACh 
binding site. Local anesthetics and other compounds such as phencyclidine bind to the 
receptor at the site of the sodium channel and modulate the binding of acetylcholine to the 
active site. Local anesthetics also prevent ion conductance through direct actiori on the 
channel. The nicotinic cholinergic receptor shares sorne properties with the sodium 
channel. 
Acetylcholine binds to the a-subu~its of the receptor, making the membrane more 
permeable to cations and causing a local depolarization. The local depolarization spreads to 
an action potential or leads to muscle contraction when summed with the action of other 
receptors. Nicotinic receptors possess a relatively low affinity for acetylcholine at rest. At 
high concentrations of acetylcholine, the affinity of the receptor for acetylcholine becomes 
higher and it subsequently becomes desensitized. The ion channel is open during the active 
state and local anesthetics may bind to it. 
As discussed in section 2.3, there is a connection between nociception, BP and 
baroreceptors. Khan et al. (94) suggest that the cholinergic nicotinic receptors are 
candidates for nociception and hyper-responsiveness ofBP. If our negative BP QTL is in 
fact the same as the one in Khan's study, then there is a possibility that BP variation due to 
salt sensitivity (high salt diet) is somehow connected to nociception, which in tum is 
associated to cholinergic nicotinic receptors and baroreceptors. Knockout mouse strains 
lacking the genes encoding the subtypes a5 and ~4 of the nicotinic receptors showed 
cardiac autonomic dysfunction, affecting the heart rate response to vagal electrical 
stimulation. In humans, although intragenic polymorphisms on the nicotinic receptor 
subunits have been identified (42,110,157), these gene mutations have not yet been 
associated with cardiovascular phenotypes. Perhaps there is a relationship between heart 
rate and BP, which may eventually be clarified by finding the specific alleles on rat 
chromosome 8 ofC8S.L1 that cause hypotension. 
5.6.2.6 Dopamine Receptor 2 
The brain dopamine system is organized into four anatomically distinct pathways. 
Each ofthese pathways is associated with particular neural functions and disease states. 
Further separation and refinement of dopaminergic function is achieved, in part, via actions 
at different receptor subtypes. Dopamine mediates its neural effects via actions at both 
presynaptic and postsynaptic dopamine receptors. Five separate dopamine receptor 
subtypes have been identified, aH belonging to the transmembrane channel G-protein 
coupled receptor family. 
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The DRD1-1ike subfamily, comprised ofDRD1 and DRD5 subtypes, is 
differentiated from the DRD2-like subfamily, which contains subtypes DRD2, DRD3 and 
DRD4. These subfamilies are distinguished from each other by their phannacological and 
signaling properties. DRD l-like receptors stimulate signal transduction by coupling to Gs 
proteins and subsequent activation of adenylyl cyclase and cAMP production. DRD2-like 
receptors couple to Gi/o-like proteins and suppress signal transduction via inhibition of 
adenylyl cyclase and cAMP production as weIl as modulation of ion channels. 
Intra-renaIly produced dopamine plays an important role in the regulation of renal 
sodium excretion. The dopamine-induced natriuretic mechanism is activated during high 
salt intake, and attenuated dopamine-induced natriuresis is thought to be involved in the 
mechanism of salt sensitivity in BP. Both DRDI-like and DRD2-like receptors are present 
in the kidney. Although it is weIl established that DRD1-like receptors mainly mediate 
dopamine-induced natriuresis, it is not clear what independent role DRD2-like receptors 
may perfonn in renal tubular and vascular functions. 
Results of in vitro experiments have suggested that DRD2-like receptors are 
necessary to potentiate DRDl-like receptor-induced natriuresis in renal tubular cells. The 
dopamine receptors in renal tubules play a central role in the regulation of tubular sodium 
reabsorption. 
DRD2 is an adrenergic receptor. DRD2 receptors are expressed in the renal tubules. 
It has not been detennined whether DRD2 is involved in the mechanism of sodium 
handling and BP control. Ueda et al.(189) have investigated the function ofDRD2 in mice 
with a disrupted DRD2 gene (DRD2 knockout mice). Six-week-old male DRD2 knockout 
mice and wild-type mi ce were fed high-salt or low-salt diets for 8 weeks. The high-salt diet 
caused a significant elevation in systolic BP in the DRD2 knockout mice but not in wild-
type mice. There was a high level of sodium retention in DRD2 knockout mice placed on 
the high-salt diet. Administration ofnemonapride, a specific DRD2-like receptor 
antagonist, to wild-type mice given 0.9% NaCI in drinking water caused suppression of 
urinary sodium excretion but had no effect in mice without salt loading. This effect 
suggested to the researchers that DRD2 receptors promote sodium excretion during a period 
of high salt intake and that a defect in this mechanism may result in sodium-dependent BP 
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elevation, since DRD2 knockout mice also show increased BP and susceptibility to sodium-
induced hypertension. 
In transgenic DRD2 knockout mice, it was found that DRD2 plays a significant role 
in sodium excretion in response to sodium loading. A defect in this system may be a cause 
of sodium-sensitive hypertension. Therefore, it is thought that the sodium retention in 
DRD2 knockout mi ce was caused by the loss of function of DRD2 in the renal tubules. It 
was found that mice without DRD2 displayed an impaired ability to excrete an excessive 
sodium intake, resulting in a significantly high level of sodium retention and sodium-
related BP elevation. The DRD2 mediated modulation of sodium excretion had a 
significant impact on total body sodium balance specifically during high sodium but not 
low sodium intake. This indicated that DRD2 is involved in the mechanism for natriuretic 
response to sodium loading, and that DRD2 is one of the key factors that determine the 
sodium sensitivity ofBP. The precise mechanism ofthis effect remains to be determined. 
5.7 ProposaIs for Future Research 
5.7.1 QTL-QTL Interactions 
It would be interesting to investigate how the BP QTLs found on chromosome 8 in 
the S rat relate to BP QTLs found on other chromosomes and how they interact. Methods 
involving linkage analysis, coupled with epistatic QTL mapping, which partition 
individuals of a F2 generation according to the genotypes at multiple loci and measures a 
phenotype, simultaneously, are available for a global genome search for epistatic 
interactions( 15). They indicate possible regions that need further investigation. Since these 
types of studies are essentially linkage analyses, as they are based on probability, not on 
certainty, they must be verified by double congenic strains. 
Double congenic strains are created when two different regions containing BP 
QTLs are transferred simultaneously to a permissive genetic background. Such strains 
could be used to assess how various BP QTLs interact with each other. Epistatic 
interactions between BP QTLs have already been found on chromosomes of the S rat using 
double congenics (31). This method allows one to de scribe the relationships between the 
different BP QTLs without knowing the specific physiological role that each gene plays. 
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5.7.1.1 Double Congenies within the Same Chromosome 
It will be interesting to examine if rat strains combining the two QTLs isolated in 
the CUITent study would retain or lack the salt-sensitive nature of the S strain. Another 
question is whether such a combination would have higher or lower BP than S rats. By 
constructing a double congenic strain within the same chromosome, one could investigate 
these effects as well as possible epistatic effects due to the combination. 
5.7.1. 2 Double Congenies Using Different Chromosomal Segments 
It would also be interesting to know whether and how the isolated BP QTLs in 
chromosome 8 interact with BP QTLs that have been isolated on other chromosomes. Will 
the effects of the BP QTLs on the different chromosomes cancel each other? Is one of the 
QTLs dominant over the other? Are there epistatic effects? These questions can be 
answered by constructing double congenic strains with chromosomal fragments from 
different chromosomes. 
5.7.1.3 Construction of Congenies Using Other Contrasting Strains. 
This study could have missed sorne BP QTLs because the alleles for BP QTLs 
could be the same in both LEW and S rats. Since there would be no apparent difference in 
the measured BP, such QTLs would be overlooked. A more comprehensive way to study 
BP QTLs located on rat chromosome 8 is to create congenic strains using other contrasting 
strains such Wistar-Kyoto, Milan, or SHR rats. In this way one would reduce the chances of 
missing a QTL (44,45,98,144). 
Moreover, it would be ofinterest to see if the high mortality rate ofC8S.L2 is 
attributable to the transducer surgery, is a result of the specific strains crossed, or is a result 
oftheir elevated BP, as suggested earlier. Regions homologous to the positive BP QTL 
could be transferred from other normotensive strains into the genetic background of S, to 
see whether the hyper-hypertensive nature ofC8S.L2 is specifically due to the alleles 
transferred from the LEW strain, and whether other norrnotensive strains have the same 
alleles. 
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5.7.1.4 Narrowing the QTL Regions Using Congenies. 
The QTL regions isolated in this study are quite large. This fact was made more 
evident from the sequence of the rat genome, which indicates that the negative BP QTL 
spans approximately 60,000,000 bp, while the positive BP QTL spans 25,000,000 bp. 
Using congenic strains, the QTL regions can be refined, as mentioned earlier, until the 
region of interest spans from 1 to 2 cM. In this way, gene sequencing could be performed to 
look for specific mutations causing elevated BP. 
5.7.2 Functional and Positional Candidate Genes 
Once high-resolution mapping methods and the delineation of the QTL regions by 
congenies results in a narrower region, spanning 1 to 2cM, the question remains ofhow to 
determine which genes correspond to the QTL. 
Co-segregation of intragenic recombinant genotypes in a candidate gene with the 
QTL phenotype would be strong evidence that the QTL corresponds to the candidate gene. 
Functional complementation, in which the trait phenotype is rescued in transgenic 
organisms, is another method for gene identification. These methods are facilitated by 
QTLs with pronounced effects, and which have a dominant gene action. 
Ifthe effect ofthe QTL was not large, it would be necessary to construct multiple 
independent transgenic lines to account for changes in expression of the transgene due to 
different insertion sites. 
The number of genes that are present within the narrower region becomes smaller 
and thus allows for the sequencing of those genes within the parental lin es. By sequencing, 
one might be able to find mutations, such as frame shifts and translocations. 
5.7.2.1 Analysis of DifferentiaI Gene Expression 
As the QTL region is narrowed through mapping, the number of candidate genes 
becomes smaller. Eventually one should examine compare the parental strains and the 
congenic strains to locate differential gene expression of possible candidate genes (such as 
those discussed in section 5.6) located in the QTL regions. Possible qualitative and 
quantitative approaches for differential gene expression analysis include Northem blot 
analysis, real-time PCR and micro-array analysis. 
The Northem blot analysis remains the standard for detection and quantification of 
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mRNA levels. In this technique, sample RNA is separated by electrophoresis on a 
denatured agarose gel transferred to a solid support and immobilized. An RNA or DNA 
probe, radiolabeled or not, is then used to detect the message of interest. Typically, 
ethidium bromide-stained or radiolabeled RNA markers are run on the same gel as sample 
RNA to provide an accurate sizing ladder in gels or on autoradiographs. Technically, this 
analysis presents several important advantages. First, the method is "low-tech" in that it 
uses standard electrophoresis equipment and requires minimal finesse in the physical 
processing of samples. The RNA undergoes very little manipulation; no enzymatic 
reactions or amplification need be carried out before analysis. 
Northem blot analysis is the easiest method for detennining both transcript size and 
the presence of altematively spliced or multiple transcripts generated from a single locus. It 
allows a direct relative comparison of message abundance between samples on a single 
blot. Northem blotting is versatile in the type of probe that can be used for hybridization. 
High specifie activity random-primed or PCR-generated DNA probes, in vitro transcribed 
RNA probes, and oligonucleotide probes can aIl be used successfully. Additionally, probes 
with only partial homology may be used. 
There are limitations associated with Northem blot analysis. First, if RNA samples 
are even slightly degraded, the quality of the data and the ability to quantifY expression are 
severely compromised. Northem blot analysis is also less sensitive than reverse 
transcription coupled with PCR (RT-PCR). 
RT-PCR has revolutionized the study of gene expression. It 1s possible to detect the 
RNA transcript of any gene regardless of the amount of starting material or the relative 
abundance of the specifie mRNA. In the RT-PCR method, an RNA template is copied into 
a complementary DNA (cDNA) transcript using a retroviral reverse transcriptase. The 
cDNA sequence of interest is then amplified exponentially using PCR. Detection of the 
PCR product is typically performed by agarose gel electrophoresis and ethidium bromide 
staining or by the use of radiolabeled nucleotides or primers in the PCR( 179). 
RT -PCR is one of the most sensitive techniques currently available for mRNA 
detection and quantification. Since most RT-PCR methods amplifY only a few hundred 
bases rather than the complete mRNA sequence, the sample RNA can be slightly degraded. 
RT-PCR can be used for relative or absolute quantification. Relative quantification 
compares transcript abundance across multiple samples, using a co-amplified internaI 
control, which ideaIly has invariant expression within those samples, for sample 
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normalization. Absolute quantification using competitive RT-PCR measures the absolute 
amount of a specific rnRNA sequence in a sample. Dilutions of a synthetic RNA (identical 
in sequence, but slightly shorter than the endogenous target) are added to sample RNA 
replicates and are co-amplified with the endogenous target. The PCR product from the 
endogenous transcript is then compared to the concentration curve created by the synthetic 
"competitor RNA." It is also possible to do real-time RT-PCR quantification by measuring 
an internaI control in replicate samples. Because ofits sensitivity, the technique ofRT-PCR 
requires that samples be free of genomic DNA or other DNA contaminants. RT-PCR can 
be a very technically challenging RNA quantification method.It often requires substantial 
pre-experimental planning to design suitable prim ers and controls(141,179). 
Microarray analysis has become a popular technique for identifying differentially 
expressed genes. It is a very costly method. Once specific mRNAs are identified, their 
expression levels must be confirmed using another previously described technique. 
Each of the techniques described can be used to determine precisely the level of a 
specific RNA within a population. In practice, each technique has inherent technical 
advantages and limitations. 
5.8 Conclusion 
In this study, two QTLs in close proximity on rat chromosome 8 were separated by 
the use of congenic strains. One QTL has a BP-Iowering effect, whereas the other has a BP-
raising effect, compared to the Dahl salt sensitive S rat. The BP-raising QTL was not 
detected in linkage analyses. As a result of applying the congenic strategy, a strain with 
higher BP even than that of the hypertensive strain S was produced. This strain differs from 
the S strain by about 20 cM in the genome. 
This study is the first step in refining the study ofBP regulating genes on rat 
chromosome 8 and understanding the precise way in which they are implicated in the 
control ofBP. A fine mapping of the QTLs in question wou Id aid in identifying the exact 
portion of the human chromosome with which the rat chromosome has a conserved 
synteny, and eventually help unravel sorne of the genetic determinants in human 
hypertension. This further refinement will enhance our understanding of the various 
mechanisms already known (see Chapter 1.5), and might even contribute to the discovery 
of new mechanisms of BP regulation. 
Through comparative genomics (Figure 25), the information gathered from humans, 
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rat and mice is integrated to obtain a clearer picture of the genes implicated in essential 
hypertension (84). As the genome projects for the human, the mouse and the rat progress, 
the genomic information will converge and might also contribute to the identification of the 
BP QTLs in humans (see Figure 25). 
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Comparative genomics integrates the information gathered from humans, rats and mice to 
obtain a clearer picture of the genes implicated as causative in essential hypertension. In rats, 
QTL mapping through the use of congenics and consomic panels is used to narrow down 
candidate genes. Congenic strains can be used in functional genomics and therapeutic 
screening. Mice are of great use in identifying the structural or functional action of discovered 
genes and for validating the importance of candidate gene knockouts. One of the advantages 
of the mouse as a model organism is the availability of gene knockout technology. In humans, 
through linkage and association studies, the information gathered from comparative mouse 
and rat genomics can culminate in clinical research, once drugs that can modify or affect 
disease genes are discovered. Diagram based on figure 1 in Jacob and Kwitek (84). 
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